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ABSTRACT 
Recent advances in genome sequencing technologies provided 
unexpected opportunities to characterize individual genomic landscape and 
identify mutations relevant for diagnosis and therapy in clinics. Specifically, 
whole-exome sequencing for complex disease (such as tumor/normal 
matched sample) and target resequencing for Mendelian disease, using 
next-generation sequencing (NGS) technologies, are gaining popularity in 
the human genetics community due to the moderate costs and the huge 
quantity of information provided by each experiment. However, NGS data 
analysis still remains the crucial bottleneck in this approach because of the 
great amount of data containing millions of potential disease-causing 
variants and difficulties involving the integration of different sources. 
Here, we describe the application of a bioinformatics analysis pipeline for 
NGS data in two case studies about rare cardiac diseases. The case 1 is 
focused on the target sequencing of 158 candidate genes in 91 patients 
affected by Brugada Syndrome (BrS). To date the clinical phenotype is 
associated with mutations in the SCN5A gene but explain only the 30% of 
the BrS cases. Therefore we selected a panel of genes previously 
associated to cases of arrhythmogenic disorders in literature and we 
analysed them in a cohort of BrS patients, which were negative for known 
SCN5A mutations. We found 98 novel genetic variations and 60 clinical rs 
belonging to 70 genes. In particular we found 13 genes significantly 
mutated in our cohort compared to healthy controls in 1000 Genomes data 
that were not previously associated to BrS phenotype. 
In case study 2 we performed a whole-exome sequencing experiment of 
trio family where the child is affected by a severe cardiac disease with 
unclear diagnosis. We developed a specific bioinformatics pipeline to filter 
out the germline mutations. We found six genes with novel deleterious 
mutations that were homozygous in the affected child, and heterozygous in 
both parents. Among the six mutated genes the TRDN and UNC45A genes 
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were already associated to cardiac dysfunctions in literature. Functional 
studies will be performed to evaluate the involvement of the mutated genes 
in the disease onset. 
In conclusion, we developed an automatic and versatile pipeline to analyse 
NGS data coming from whole-exome sequencing and target sequencing 
strategies. In addition, we integrated in the pipeline several public variation 
databases to evaluate and interpret the candidate mutations. The 
mutations found were validated by Sanger sequencing to evaluate the 
strength of the pipeline filters. 
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SOMMARIO 
I recenti progressi nelle tecnologie di sequenziamento del genoma umano 
hanno offerto opportunità inaspettate per la caratterizzazione del 
patrimonio genetico di un individuo e per l’identificazione di mutazioni 
rilevanti per la diagnosi e la terapia in clinica. In particolare, il 
sequenziamento dell’esoma per malattie complesse (come il confronto a 
coppia campione tumorale / campione normale) e il risequenziamento di 
regioni target applicato alle malattie genetiche di tipo Mendeliano, mediante 
sequenziamento di ultima generazione di tecnologie (NGS), stanno 
diventando molto popolari nella comunità di genetica umana grazie ai costi 
moderati e alla quantità di informazione fornita in ogni esperimento. 
Tuttavia, l’analisi dei dati NGS rimane ancora il collo di bottiglia in questo 
approccio a causa della grande quantità di potenziali varianti causative e 
della difficoltà di integrare i dati con fonti diverse. 
Qui, descriviamo l'applicazione di workflow bioinformatico per l’analisi di 
dati NGS in due casi clinici riguardanti malattie cardiache rare. Il primo 
caso è focalizzato sul risequenziamento di 158 geni candidati in 91 pazienti 
affetti da Sindrome di Brugada (BrS). Ad oggi il fenotipo clinico è associato 
a mutazioni del gene SCN5A ma spiega solo il 30% dei casi BrS. Pertanto, 
abbiamo selezionato un gruppo di geni precedentemente associato a casi 
di disturbi aritmogenici in letteratura e li abbiamo analizzati in una coorte di 
pazienti affetti da BrS che non presentavano mutazioni conosciute in 
SCN5A. In totale, abbiamo trovato 98 varianti genetiche (SNP/INDEL) e 60 
rs clinici appartenenti a 70 geni del nostro pannello. In particolare, abbiamo 
trovato 13 geni mutati in modo significativo nella nostra coorte rispetto ai 
controlli sani ricavati dal progetto 1000 Genomes. Questi geni non sono 
mai stati in precedenza associati ad un fenotipo di tipo BrS. 
Nel secondo studio abbiamo condotto un esperimento di sequenziamento 
sull’intero esoma di un trio (genitori e figlio) in cui il bambino è affetto da 
una grave malattia cardiaca con diagnosi non chiara. Abbiamo sviluppato 
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uno specifico workflow di analisi bioinformatica per filtrare le mutazioni 
germinali. Abbiamo trovato sei geni con nuove mutazioni deleterie presenti 
in stato di omozigosi nel bambino affetto ed in eterozisi in entrambi i 
genitori. Tra i sei geni mutati, i geni TRDN ed UNC45A erano già associati 
a disfunzioni cardiache in letteratura. Gli studi funzionali saranno eseguiti 
per valutare il coinvolgimento dei geni mutati nell'insorgenza della malattia. 
In conclusione, abbiamo sviluppato una pipeline automatica e versatile per 
analizzare i dati NGS provenienti da esperimenti di sequenziamento 
dell’intero esoma e da strategie di sequenziamento di tipo target. Inoltre, 
abbiamo integrato i dati mutazionali con diverse banche dati pubbliche per 
valutare e interpretare le mutazioni candidate. Le mutazioni trovate sono 
state inoltre convalidate dalla metodica di sequenziamento Sanger per 
valutare la forza dei filtri utilizzati nella pipeline di analisi. 
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1. INTRODUCTION 
1.1. Next-Generation sequencing technology 
1.1.1. The advent of next-generation sequencing technology 
Over the past five years, the massively parallel DNA sequencing 
technology has become widely available thanks to the previous innovative 
development in sequencing strategies [1, 2]. The advent of next-generation 
sequencing (NGS) has rebuilt the meaning of DNA sequencing by 
processing millions of DNA fragment in parallel resulting a very low cost per 
base and a throughput on the gigabase (Gb) scale [3] (Figure 1). The 
enormous volume of data cheaply produced by (NGS) technology has been 
the drawing power for shifting from automated Sanger sequencing and 
changing the way of thinking the genome research and clinical genetics [4]. 
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Figure 1 Sequencing costs trend. The rapid development of the NGS technology 
marked in 2008, the free-fall of the sequencing costs. 
(http://www.genome.gov/sequencingcosts/) 
The powerful and flexible nature of the NGS technology led to the 
development of a broad range of applications allowing researchers to ask 
biological questions that were unimaginable just a few years ago. The 
broadest application of NGS may be the resequencing of human genomes 
to enhance our understanding of how genetic differences affect health and 
disease. 
Despite a variety of NGS features allowed several companies to develop 
high-throughput sequencer machines, the general NGS workflow is well-
defined and is divided into three steps classified by template preparation, 
sequencing and imaging [4]. The specific combination of protocols is 
unique for each technology and determines the type of data produced from 
each platform. 
Three methods were strongly developed and standardized for NGS called 
(1) clonal amplification, (2) sequencing by synthesis and (3) real-time 
sequencing [4] (Figure 2). 
	   3	  
 
Figure 2 NGS sequencing strategies. Representation of available template 
immobilization strategies adopted by sequencing companies. [4] 
The first two methods involve template amplification. In detail the clonal 
amplification is based on emulsion PCR (emPCR) where bead–DNA 
complexes are encapsulated into single aqueous droplets in oil emulsion 
and PCR amplification creates thousands of copies of the same template 
within each droplet. Afterward each amplified bead are immobilized on a 
solid plate (PicoTiterPlate) and ready for sequencing and imaging. This 
sequencing method is on the basis of the Roche/454 platforms (Figure 2a) 
The sequencing by synthesis does not require a PCR step but the template 
amplification is performed directly on a solid support. Illumina and Helicos 
BioSciences platforms use this method with some modifications between 
each other (Figure 2b,c,d). The most recent method and the one with no 
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template generation is the real-time sequencing which is capable to directly 
sequence DNA fragment by involving a DNA polymerase immobilized on a 
solid support and the continuous incorporation of dye-labelled nucleotides 
during DNA synthesis (Figure 2e). 
1.1.2. Illumina sequencing technology workflow 
The whole NGS workflow consists on a three-step process divided into 
template preparation (or sample preparation), sequencing and imaging. 
The Illumina sequencing strategy is based on the concept of sequencing by 
synthesis to produce millions of ‘short-read’ (from 36 to 86 nucleotides of 
length) simultaneously (Figure 3) [5]. The first step is the creation of a DNA 
library by and adding universal adapters by ligation to sample DNA 
fragments. Afterward, the process involves using a microfluidic cluster 
station to add these fragments to the surface of a glass flowcell thanks to 
the hybridization with complementary oligos to the surface. Each flowcell is 
divided into eight lanes where the interior surfaces have covalently 
attached oligos complementary to the specific adapters that are ligated 
onto the library fragments. The hybridization of the library fragment on the 
flowcell is followed by a subsequent incubation, called cluster generation, 
that amplifies the fragments in a discrete area or ‘cluster’ thanks to a PCR 
reaction called ‘bridge PCR’ [6] directly on the flowcell surface. The flowcell 
is placed within the sequencer where each cluster is supplied with 
polymerase and four differentially labeled fluorescent nucleotides that have 
their 3’-OH chemically inactivated to ensure that only a single base is 
incorporated per cycle [5]. Every cycle is composed by (1) base 
incorporation, (2) imaging step to discriminate the incorporated nucleotide 
at each cluster by laser light excitation and (3) a chemical step that 
removes the fluorescent group and release the 3’ end for the next base 
incorporation cycle (Figure 3). 
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Figure 3 Illumina Genome Anlayzer sequencing workflow (modified from 
Illumina website) 
The sequencing run turnaround varies depending on the number of cycles, 
which corresponds to the read length, between 3 and 10 days (36 to 85 
base pair read length). The images, corresponding to the sequence of each 
cluster, are translated into text file as FastQ format [7] containing the reads 
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produced in the sequencing run. Every run produces from 50 to 60 millions 
of reads. 
1.1.3. Capture technology 
Despite the sequencing costs are constantly falling, the whole-genome 
sequencing approach is not yet feasible for large number of samples, 
especially in clinical and biomedical research, because the cost and time 
taken are still too great [3]. Consequently, substantial efforts have been 
made to develop several ‘target-enrichment’ methods in which genomic 
regions of interest are selectively captured before sequencing. Before the 
advent of NGS there were methods for target-enrichment based on PCR 
and molecular inversion probes (MIP). Both methods reveal great 
sensitivity in enrichment, however the difficulty of use grows with the 
number of genes in the target to enrich [3]. 
A widely used method in NGS for target-enrichment is the DNA capture 
based on hybridization of the genomic region of interest with 
complementary oligonucleotides (probes) properly designed (Figure 4). 
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Figure 4 Capture enrichment technology. Two main strategies to select specific 
DNA target sequence: array-based capture (left) and solution-based capture (right). 
Modified from [3] 
The capture selection has overcome the other existing method for its ease 
to use and for the scalability power [3]. Firstly this methodology was applied 
to a solid array with immobilized probe (on-array capture) [8, 9], but 
working with microarray support requires expensive hardware. Moreover 
the starting DNA amount required for library preparation is relatively large 
(around 10–15 µg) which is not easy to collect in particular experiment 
such as sorting cells [3]. To overcome some of the disadvantages present 
in the on-array capture it has been also developed a solution-based target-
enrichment strategy. This methodology has the same principle of 
hybridization but the probes are in solution and are in excess number 
allowing much less DNA amount for library preparation compared to other 
methods [10]. 
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This technology allows capturing the entire ‘exome’ (all the coding exons in 
the human genome) to a particular genomic region (from 20 kilobases to 5 
megabases) with the ‘target’ design. 
1.1.4. Agilent solution-based target enrichment 
The Agilent target enrichment is based on the hybridization of 
complementary probes with genomic DNA region. Basically the workflow 
consists in three steps, which consider hybridization, bead capture and 
sequencing (Figure 5) 
 
Figure 5 Agilent solution-based capture workflow. Briefly the genomic DNA 
sample is prepared as NGS library and hybridized with the specific Agilent 
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biotinylated probes. The targeted regions are selected using streptavidin coated 
magnetic beads which link only the hybridized probes with the complementary 
DNA sample. The enriched library is amplified and ready to sequence. 
(http://goo.gl/nLLyby) 
Briefly the genomic DNA is shared and the adaptors ligation is performed to 
obtain a DNA library. The hybridization step is performed between the 
library and probes (120 nucleotide length) complementary to the genomic 
region to capture. Magnetic beads will select only those DNA strands that 
have been recognized by a probe and those with no probe recognition will 
be wash away. The enriched library is built and ready for sequencing. 
Agilent developed several standard kits for the exome capture for a few 
organisms (human, mouse). In addition to the standard kits, it is also 
possible to create a custom target region to capture thanks to the Agilent 
SureSelect site (https://earray.chem.agilent.com/earray/). Based on 
genomic region of interest the site computes the complementary probes to 
cover the target range. The computed probes will be synthetize and the 
custom hybridization solution will be ready for use. 
 
1.2. Bioinformatics analysis 
 
As NGS has become a popular, whole-genome sequencing and whole-
exome sequencing have proven to be valuable methods for the discovery 
of the genetic causes of rare and complex diseases [11]. Nevertheless, the 
great amount of data and the number of simple nucleotide variations 
(SNVs), including single-nucleotide polymorphisms (SNPs) and small 
insertions and deletions (INDELs) divert the problem to the computational 
analysis and data management which are the real bottleneck of the entire 
NGS workflow [12]. 
On average, whole-exome sequencing identifies from 12,000 to 20,000 
variants in coding regions [13, 14], of which ≈90% are found in publicly 
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available databases [15]. To get meaningful biological results, each step of 
the analysis workflow needs to be carefully considered, and specific tools 
need to be considerate based on different experimental setups [16]. 
The bioinformatics analysis process for NGS data is divided in different 
steps involving alignment, variation discovery and annotation (primary 
analysis) as well as the use of tools for gene prioritization and mutation 
pathogenicity prediction (secondary analysis). The final aim is to select 
potentially driver mutations related to a given disease. 
1.2.1. Computational tools and analysis pipelines 
The bioinformatics analysis of NGS data is a complex process divided into 
different steps, which consist of a big collection of programs and databases 
and involve the management of huge amount of heterogeneous data [16] 
(Figure 6). The primary analysis of a typical whole-exome/target 
sequencing project is divided into three main steps: (1) quality filtering (2) 
read alignment, (3) variant identification or SNV call and (4) variant 
annotation. Generally those steps are recursive and, in the last year, 
several groups developed its own pipeline in order to standardize the 
results and speed-up the whole process by using different combination of 
tools for each single analysis step [17–19]. 
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Figure 6 Schematic data analysis workflow for NGS experiment. After library 
preparation and sequencing the raw reads are ready for bioinformatics analysis. 
The reads pass through different quality filters before the read alignment and the 
successively variant identification. The mutations found are annotated to infer the 
biological relevance and prioritized to select a candidate set of deleterious 
variations. [16] 
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1.2.1.1. Quality filtering 
The very first step, after completing the sequencing run, is the evaluation of 
the read quality produced by the high-throughput sequencer. Generally all 
the sequencing platforms are prone to base-calling error, contamination or 
sequence artefacts [16]. Quality check becomes a crucial step to evaluate 
the raw reads and try to eliminate or correct the errors introduced by the 
sequencer itself. 
Several tools have been developed to perform different stages of quality 
assessment and to produce valuable summary reports. For example  
FastQC (http://goo.gl/vuP5aj) is multi-platform stand-alone software, which 
have the possibility to visualize the raw reads statistics with intuitive plots. 
Other similar tools to FastQC, specific for short-read coming from Illumina 
technology, are htSeqTools [20] and SolexaQA [21] that are also able to 
process the data and discard reads with low quality value or trim them 
where the base-call quality is poor. 
1.2.1.2. Read alignment 
After the quality step, the reads are ready for to be mapped against the 
reference genome [22]. In case of human sample, the reference genome 
assembly is available in two versions: the one curated by the University of 
Santa Cruz (UCSC) which is hosting the ENCODE data [23] and the one 
available from the Genome Reference Consortium (GRC), which focuses 
on creating reference assemblies (http://www.ncbi. 
nlm.nih.gov/projects/genome/assembly/grc). 
This specific task is the hardest step in light of computational resources, 
considering the whole data analysis process. Therefore the alignment of 
millions of reads back to a reference genome required an improvement and 
a development of new specific tools which are able to rapidly solve this 
issue [24]. In the last five years a plethora of aligner have been developed 
[25] which are mainly based on the construction of data structures named 
‘index’ in order to compress the genome reference or the raw reads and 
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speed-up the alignment. The two main algorithm categories used for the 
majority of the aligner are (1) the hash table and (2) the suffix tree [24]. 
The hash table is a relatively old concept that was originally applied on the 
BLAST [26] software and successively adopted by few fast aligner such as 
MAQ [27], SOAP [28] and SeqMap [29] and following a seed-and-extension 
paradigm. All those software are based on the ‘seed searching’, as in 
BLAST program. Once the reads and the reference are indexed in a hash 
table, a portion of each read (seed) will be aligned with the reference 
sequence. The seed searching allows also mismatch, which improve the 
speed, and once the seed match between the read and the reference 
genome is found, it extends the partial match in order to places the read in 
the correct genomic location [24]. 
The other algorithm, based on the suffix-tree, also follows the concept of 
seed-and-extension paradigm but the reads and reference indexes are built 
in a suffix-tree data structure (Figure 7).  
 
Figure 7 Suffix-tree algorithm representations. The different bubble trees 
(A,B,C,D) represent the organization of prefix tree of the AGGAGC example string. 
The table E shows the construction for the suffix array and Burrows-Wheeler 
transform of AGGAGC string. [24] 
The suffix-tree structure allows a fast string matching by handling the 
‘suffix’ (strings representing the entire reads/reference variability) as index 
data [24]. Link between the index and the suffix data is obtained by the 
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Burrows-Wheeler Transform (BWT) [30]. This data structure form the basis 
of recently developed softwares such as BOWTIE [31], BWA [32] and 
SOAP2 [33].  
All the software cited before perform a fast and accurate mapping of the 
reads against the reference genome by producing a file in SAM/BAM [34] 
format. This format has been introduced by 1000Genomes Project [35] and 
rapidly became the standard format for storing the alignment data. To 
manipulate those particular files the 1000Genomes Project also developed 
a tool suite called samtools [34] that allows management and filtering in a 
very efficient way. 
The SAM/BAM alignment data are the input files for the next step in the 
analysis process that will be the core task of the primary analysis that is the 
variant identification. 
1.2.1.3. Variant call 
After read alignment and once the SAM/BAM file is produced the next step 
is the identification of those position that differs from the reference 
sequence and could be recognized as variations (Figure 8). 
 
Figure 8 Visualization of single nucleotide variant found in read alignment. 
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The variation identification, or SNV calling, is performed by specific tools 
that can be divided into two categories: (1) simple allele count and (2) 
probabilistic method [22].  
The simple allele count method has been the first algorithm implemented 
for variant calling [22]. It is simply based on the count of the alleles in each 
position of the genome and the genotype is inferred by the number of non-
reference allele found. If the proportion of non-reference allele is between 
20% and 80% will be called a heterozygous genotype, otherwise a 
homozygous genotype would be called [22]. This method is the simplest 
way to call variations and infer a genotype but is very dependent on the 
heuristic filters imposed by the users such as minimum base quality score 
(Phred score), read depth threshold and read mapping quality [22, 36]. This 
method has been embraced by several commercial software such as 
Roche GsMapper, CLC Genomics workbench and DNASTAR LaserGene 
software [22]. 
Most recently, newer software adopts the probabilistic method as engine of 
their tool. This method used the base quality score to calculate a posterior 
probability for each genotype call [27, 33]. This calculation dramatically 
improve the accuracy of genotype caller by giving a quality score for the 
genotype status of each variations [22]. Several software are based on this 
probabilistic method [33, 34] but one of the latest and most sophisticated 
software is GATK [37]. Its characteristic is the improvement of the input 
BAM file with a recalibration tool (BaseRecalibrator walker) which 
recalculate the base quality score of each aligned read by using a model on 
known variation site [37]. This particular procedure slightly improves the 
overall quality of calls and is one of the standard step for data preparation 
in the guidelines of the GATK software 
(http://www.broadinstitute.org/gatk/guide/best-practices). 
As for the alignment, the variant calls are stored into a text file, which 
follows the standard of 1000Genomes data called VCF (variant call format) 
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(http://www.1000genomes.org/wiki/Analysis/Variant%20Call%20Format/vcf
-variant-call-format-version-41). Basically it is a column-based file in which 
nine columns contain the specific information for each variant call including 
chromosomal location, reference and alternative allele, variation quality and 
the depth of the read supporting the alternative allele compared to the 
number of read supporting the reference allele (Figure 9). 
 
Figure 9 Example of VCF file. 
Thanks to the information given by this file and a suite of tools called 
vcftools [38] the end-user can easily filter-out those record with low variants 
quality score or variants that does not satisfy the user heuristic filters (such 
as read depth) indeed producing a high-quality VCF containing the variants 
of each sample sequenced. 
The next step to evaluate the significance and the possible function of each 
variation called is the annotation step. 
1.2.1.4. Annotation 
Once the VCF file containing the quality-passed call has been produced, 
the annotation step gives, to variants, additional information regarding the 
possibility to predict their functional impact [22]. Generally, the annotation is 
performed by linking the variation data to existing public databases. This 
process became automatic thanks to software able to rapidly aggregate 
information coming from different databases to the VCF file such as 
ANNOVAR [39] and SnpEFF [40]. Basically those programs supply two 
type of annotation including information about the type of variants relative 
to known transcripts and functional implication by using database for 
pathogenicity prediction or conservation score. 
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Indeed each variant can be classified as intronic or coding variant. For 
single-nucleotide coding variants, can be predicted if the variation 
corresponds to a synonymous, missense or nonsense mutation relative to 
the protein coding sequence. 
This basic annotation can be improved by using several resources such as 
public variants database and pathogenicity prediction tools, which will be 
discussed in the next paragraphs. 
1.2.1.5. Public variation databases 
The number of variations found in a typical exome sequencing experiment 
are approximately 20,000 variants [14] and searching for few candidate 
variants could be a tricky part. The use of public variations database has 
become necessary to annotate and filter out those variants that are 
commonly found within the human population. The three most used 
databases in NGS data analysis are the following: 
1.2.1.5.1. dbSNP 
The Single Nucleotide Polymorphism Database (dbSNP) is a free public 
database for genetic variation, including both polymorphisms and variations 
associated to diseases, across different species [41]. In particular for 
human population, the dbSNP has been created to support research in 
several applications such as genetic population studies, investigations into 
evolutionary relationships and pharmacogenomics [41]. Over the last five 
years the dbSNP repository had rapidly growing thanks to the different 
consortia and large sequencing project (Figure 10) [42]. 
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Figure 10 Growth of dbSNP repository. dbSNP entries increasing trend from 
2005 to 2012. Since the advent of NGS technology in 2008, the variance of the 
submission (bold black line) and the variations validated (light grey line) is 
dramatically growing. [42] 
In the NGS era, the use of this database during the bioinformatics analysis 
became a standard procedure to filter out all the common variants, 
classified as polymorphisms to narrow down the candidate variations, 
especially in recessive disorders [43]. 
Recently, the dbSNP also contains particular variations that are classified 
as clinically associated to diseases [41]. This information is particularly 
useful in exome sequencing project to select candidate genes reporting 
those ‘precious’ variations. 
1.2.1.5.2. 1000 Genomes Project 
Started in 2008, the 1000 Genomes Project is an international study with 
the purpose to sequence at least a thousand people genomes from around 
the world to create the most detailed and medically useful picture to date of 
human genetic variation [35]. To date, more than one thousand genomes 
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have been sequenced by using various NGS methodology and platforms 
(phase 1). The final purpose is to sequence 2500 genomes. The sample 
dataset already sequenced, is composed by 1092 healthy individuals 
coming from 13 populations (http://www.1000genomes.org/). 
The phase 1 variation data produced by this huge study are completely 
available for further investigation. As for the dbSNP, the 1000 Genomes 
data are used to filter out common variations in NGS experiments. 
Furthermore, thanks to the allele frequency information calculated for each 
variant, it gives the possibility to refine the filter of common variants by 
looking at low frequency variants (>1%) within the 1000 Genomes 
population and also to evaluate the frequency difference in large dataset 
NGS project. 
1.2.1.5.3. Exome Sequencing Project (ESP) 
Another variation database, which has been recently created from the 
Grand Opportunity (GO) Exome Sequencing Project data, is the Exome 
Sequencing Project database (ESP). This database is pretty different from 
the other previously described, because the samples sequenced and 
analysed are affected by some disorders related to heart, lung and blood 
(https://esp.gs.washington.edu/drupal/). Moreover only the exome of those 
samples will be sequenced to catalogue the whole coding part of our 
genome. Many sequencing centres and hospitals are collaborating to 
sequence the exome of 8000 affected individuals. The last release (20 
June 2012) including 6500 individuals exome data, is available for 
investigation at http://evs.gs.washington.edu/EVS/ website but the medical 
record for each patients will not be released. 
Recent studies involving cardiac diseases [44–46] used this database to 
validate their findings by comparing the variation frequencies found in ESP. 
Although the medical information for the ESP individuals will not be 
released, this resource could help the clinicians and researchers to 
interpret and prioritize candidate genes in a cohort of affected samples. 
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1.2.2. Secondary analysis  
Although the development of variation database and the information quality 
available are growing constantly, the functional and biological significance 
of the vast number of mutations in the human genome are still unknown 
[47]. Testing the effect of single-nucleotide mutations required functional 
study at protein-level, which would be extremely expensive and time-
consuming for researchers [48]. 
Filtering procedures and in-silico prediction methods can ease the choice of 
the candidate genes and they can try to fill the gap between the mutation 
analysis and the disease. 
1.2.2.1. Filtering methods 
Recent genome/exome sequencing studies [14, 35, 49] have demonstrated 
that disease-causing genes are associated to missense (protein coding 
variations) mutations [48]. Approximately 50 to 75% of variants can be 
removed by focusing only on non-synonymous (protein-altering) changes 
[50, 51]. A filtering step is an efficient method to select a list of possible 
candidate variations. 
A typical variant filtration workflow includes several steps to progressively 
narrow down the number of variations and select only the most pathogenic 
ones (Figure 11). The possible candidate variants are selected on the 
assumption that (1) the causing mutations alters the protein sequence, (2) 
should be extremely rare within the population (3) the disease-causing 
variants should be present in the affected samples and (4) every affected 
individuals should carry the candidate mutations [52]. 
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Figure 11 Filtration workflow in exome sequencing experiment [52] 
The application of those heuristic filters on the NGS variants is extremely 
efficient in exome sequencing experiment for Mendelian disorders [14, 49]. 
Indeed it is highly proficient the synergistic combination between the 
variation databases to exclude harmless variation (polymorphisms and 
synonymous variants) and complete knowledge of the disease to fit the 
possible candidate variations in a correct inheritance model. 
Nevertheless many experiments sometimes missing the control samples or 
the disease picture is pretty complex (as for the tumor samples). In this 
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case bioinformatics helps the researchers with specific tools for 
pathogenicity mutation prediction to depict a list of candidate mutations. 
1.2.2.2. In-silico prediction tools 
To further investigate the possible effect of non-synonymous variants, 
several bioinformatics tools have been developed [53]. Despite the huge 
number of software developed, the mostly used prediction tools in NGS 
secondary data analysis are based on (1) the sequence conservation 
among species and (2) the variant localization within the protein structure. 
It has been demonstrated [54, 55] that the fraction of disease-causing 
missense mutation is over-represented in highly conserved region. This is 
relatively clear because the more conserved is the position the more 
fundamental it is for the protein function. GERP++ [56] and PhastCons [57] 
are the most used software to evaluate the genome-wide sequence 
conservation. Even is they developed two different algorithms, they are 
able to calculate a conservation score generated by multi alignment data 
across known species and phylogenetic tree information (Figure 12). 
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Figure 12 Calculation of conservation score workflow performed by GERP 
Other bioinformatics tools predict the pathogenic role of a missense variant 
by looking at the amino acid change type and the variant localization within 
the protein structure. Huge number of tools have been developed [53] but 
the most used in NGS for pathogenic prediction are SIFT [58] and 
PolyPhen2 [59]. SIFT calculates the probability of an amino acid change by 
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using a homology-based algorithm. It considers also the evolutionary 
conservation of each amino acid and predicts whether the substitution 
found would be tolerated or not. Polyphen2 is a Bayesian classifier that 
calculates the damage probability of a mutation on the basis of sequence 
homology and structure feature, where available. 
Several data analysis pipelines implemented all those tools to facilitate the 
use of multiple conservation and prediction tools automatically [17, 18, 60]. 
Those pipelines used a pre-computed SNP classification for each 
prediction tool. 
 
1.3. Clinical Sequencing 
 
Application of NGS technologies to Mendelian and complex diseases has 
proven to be an effective alternative to single-gene tests in research for 
establishing a new genetic basis of diseases [11, 14, 61, 62]. In particular 
the development of capture technologies for target sequencing, instead of 
whole-genome sequencing, dramatically reduced the sample preparation 
time and the overall costs of the experiment The scalability power 
introduced by capture technologies defined two experiment categories 
based on the complexity of the disease: the whole-exome sequencing for 
complex traits and large gene-panel target sequencing for routine 
diagnostic (Figure 13). 
The whole-exome sequencing would be particularly efficient for very few 
cases (<10 patients) where the standard clinical analysis (radiographic 
features, biopsy findings, karyotyping or single-gene testing) defects in 
order to find novel associated genes. On the other hand, the target 
sequencing of many candidate genes (from 50 to 250) in a large cohort of 
patients is now feasible and with a relatively low-cost per sample [63]. 
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Figure 13 Whole-exome sequencing and target sequencing in clinical 
diagnostic. Generally in diagnostics the use of NGS technology is applied 
following two main strategies: Whole-exome sequencing for few selected samples 
with a severe disease to discover novel causing genes where standard diagnostics 
procedure fails and (2) target sequencing of candidate genes to produce a 
molecular diagnostic platform to reduce the cost per sample. 
The application of this technology in clinical laboratories would be the 
perfect combination to unlock complex disease pictures and to provide 
anticipatory guidance and prognosis where other diagnostic testing has not 
been definitive [64]. 
Even if conceptually the NGS application is going to be attractive, the 
implementation as clinical laboratory standard will raise practical 
challenges. In particular three main aspects have to be considered: (1) the 
data management and analysis, (2) the reliability of the method and (3) the 
standard procedures for analysis. The huge amount of data and the 
intensive analysis process requires a bioinformatics facility core to store, 
analyse the data and interpret the results. Discussion regarding the 
analysis metrics such as read mapping, minimum depth for variant call 
sensitivity should be considered for standard guidelines. Moreover 
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technical limitations regarding the capture system should be taken into 
account for accuracy, sensitivity and precision in clinical practice [65]. 
The continuous improvement in capture technology and bioinformatics 
tools will rapidly revolutionize the concept of diagnosis in clinical field. 	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1.4. Brugada syndrome 
 
Brugada Syndrome (BrS [MIM #601144]) is an inherited autosomal cardiac 
arrhythmogenic disorder with a prevalence of 1:5000 in Western countries, 
diagnosed by the presence of a typical ECG pattern with ST-segment 
elevation and right bundle branch block [66]. BrS is characterized by 
ventricular instability, which may lead to malignant tachycardia and sudden 
cardiac arrest in young asymptomatic adults [67] and is estimated to be 
responsible for 4% of all sudden deaths (SD) and 20% of SD’s among 
patients with structurally normal hearts. The only widely accepted treatment 
of BrS is the implantation of cardioverter-defibrillator (ICD).  
In the past BrS was regarded as “monogenic” disorder [68, 69]. Today 17 
genes, mainly ion channel genes [44], are actually associated to BrS. In 
particular the SCN5A mutations account for the vast majority. Despite the 
number of genes associated has increased, approximately 70% of BrS 
cases cannot be genetically explained with the current knowledge depicting 
a complex picture of BrS genetics [44]. 
Recently Risgaard et al investigated about the relationship between 12 
genes previously associated to BrS by using the ESP data [70]. They found 
a very high prevalence of BrS mutations (1:23) in ESP data compared to 
the prevalence of BrS in general population [70]. Further investigation [44] 
consider the entire set of mutations coming from all the 17 genes know to 
be associated to BrS and they estimated an even higher prevalence of BrS 
mutations of 1:21. Despite no clinical data are available for the ESP 
samples, have been demonstrated that none of the patients are affected by 
channelopathies [71, 72]. 
On one hand these data really interrogate on the real pathogenic role of the 
newly BrS associated variants, on the other hand reveals that the use of 
new population dataset, obtained by NGS technology, is extremely useful 
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for discriminating the disease-causing instead of common variants in 
human population. 
 
1.5. Aim of the study 
The goals of this work are the following: 
1. Develop an automated pipeline to perform the primary 
bioinformatics analysis of NGS data such as quality  control, 
mapping and variant calling. 
2. Develop an annotation and database integration system to select 
and prioritize mutations probably the pathogenic role. 
To validate the application of the bioinformatics pipeline, we analysed two 
case studies with different NGS strategies: 
1. Case 1: Target sequencing on Brugada Syndrome patients. 
a. We designed a custom Agilent capture system in order to 
analyse all the coding exons of 158 selected genes in our 
cohort of 91 patients. The goal is to discover novel 
mutations in genes not previously associated to BrS. 
2. Case 2: Undiagnosed arrhythmogenic disease. 
a. We performed whole-exome sequencing of a family trio 
where the proband is the child. We will focus the analysis on 
the variation difference between the unaffected parents and 
the proband. The main purpose is to find causative 
mutations related to the severe proband phenotype. 	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2. MATERIALS AND METHODS 
 
2.1. Case 1: Target sequencing of 91 Brugada patients 
2.1.1. Patients Clinical Profile 
The investigation conformed to principles outlined in the Declaration of 
Helsinki. Written informed consent for genetic analysis was obtained. 91 
consecutive Italian BrS patients (age 50.5± 13.2, 87% males) were 
selected based on the presence of electrocardiogram (ECG) type I, either 
spontaneous (n=55) or induced by flecainide or ajmaline infusion (n=36) 
[73] (section 6.1.1) 
Patients were subjected to personal and family history acquisition, 
evaluation of blood electrolytes, 24 hours Holter-ECG, echocardiography 
and, whenever possible, cardiac magnetic resonance imaging to exclude 
the presence of other conditions associated to ST elevation. 35 patients 
were symptomatic for cardiac arrest, ventricular tachycardia 
(VT)/ventricular fibrillation (VF), or syncope, while in 56 asymptomatic 
patients diagnosis of BrS was suspected during routine ECG or family 
screening. 27 patients showed family history for SCD. Therapeutic options 
were evaluated according to current guidelines [74] and clinical judgment, 
leading to ICD implantation in 55 patients. Patients were followed at least 
yearly by clinical assessment, ECG, echocardiography and ICD check. 
Mean follow-up was 63.4± 21 months. 8 patients had a major arrhythmic 
event (SCD, documented VT/VF, appropriate ICD shock). All relevant 
clinical and genetic data were collected in an electronic database. 
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2.1.2. Genes selection 
For target sequencing we drew a panel of 158 genes that may influence 
cardiac electric conduction and have a role in the arrhythmogenic 
mechanism (section 6.1.2). In order to capture the coding region of all the 
gene in the panel, all the exons of the 158 genes has been selected. Briefly 
we downloaded all the genomic coordinates of the longest isoform for each 
gene to capture by using the information stored in UCSC Genome Browser 
tables. The probe design also included the 5’ UTR flanking the first exon for 
every gene. 
We finally performed the design of 2320 coding exons corresponding to 
498.094 nucleotides. Target capture was performed with the solution-based 
kit SureSelectXT Custom 1kb-499kb (Agilent technologies, Santa Clara, 
CA) according to the manufacturer’s version 1.0, compatible with Illumina 
paired-end sequencing library. 
We applied several criteria to choose these candidate genes. Since BrS is 
characterized by electrical instability, we selected mainly ion channels 
genes Figure 14. 
 
Figure 14 Functional categories of the 158 selected genes 
 In particular we considered the genes belonging to those 10 categories: 
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1) All subtypes of voltage gated Na+ channels because of their leading role 
in the upstroke of cardiac action potential [75–79];  
2) Voltage gated potassium, chloride and calcium channels, playing a role 
in cardiac action potential or expressed in cardiac tissue [76, 78, 80–84];  
3) Accessory subunits of sodium and potassium v-dependent channels, 
having a known modulator role on the gating of their own alpha subunits 
[76, 85];  
4) Ligand-gated channels, such as adrenergic, serotonin, nicotinic and 
muscarinic acetylcholine receptors, modulating the parasympathetic control 
of the heart via the vagal nerve activity [86–88];  
5) Ankyrins [89–91] and subtypes of calmoduline [90];  
6) Transporters and ion exchangers [76, 92];  
7) Scaffold protein such as calsequestrins [76], calreticulins [93], all genes 
associated to arrhythmogenic right ventricular dysplasia (ARVD) and 
caveolins interacting with sodium channels [92, 94, 95]; anchoring, adapter 
proteins and modulators of ECG intervals, previously associated with 
arrhythmia susceptibility [76, 81, 96–100];  
8) Gap junctions expressed in the heart and involved in other forms of 
arrhythmias [76, 101];  
9) Structural proteins involved in cardiomyopathies (such as actin family, 
myosin, lamin A/C, syntropin and desmin) [76, 92];  
10) Other genes associated with increased arrhythmic risk in BrS patients 
[102], angiotensin receptors associated with increased susceptibility to 
SCD [103] and other genes described in literature in correlation with 
arrhythmic events [76, 89, 92, 94, 97]. 
2.1.3. Target sequencing 
The wet lab workflow involved several technique for indexing, enrich and 
sequence the samples into pool of 5 to 7 samples per Illumina GAIIx lane. 
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Briefly, each DNA sample was targeted with a tag (DNA sequence) in order 
to recognize the sample after sequencing, afterward each sample DNA 
tagged were enriched with the Agilent target region probe previously 
designed. 
Genomic DNA (gDNA) of selected patients was extracted from peripheral 
blood using the automated extractor Maxwell16 (Promega, Milano, Italy); 
the concentration and high quality of gDNA (A260/280  1.8 to 2.0) was 
evaluated by Nanodrop Spectrophotometer (Thermo Scientific). 
Three micrograms of 91 gDNA patients were fragmented using the Covaris 
shearing system (Covaris inc., Massachusetts, USA). Selected regions of 
each patient were then subjected to Illumina protocols for cluster 
generation and massive sequencing. 
Paired-end multiplexed sequencing was performed on the Illumina Genome 
AnalyzerIIx platform (Illumina, San Diego, CA), combining 9 patients 
identified by different index sequences in each lane and performing 86-
cycle runs. Image analysis and base calling were performed with CASAVA 
1.7 software. 
 
2.2. Case 2: Whole-exome sequencing of Trios 
2.2.1. Family pedigree and clinical profile 
The patient is a 2-years boy born in Afghanistan. At six-month age he had 
the first episode ventricular fibrillation that led to a sudden cardiac arrest. 
After that an ICD (Implantable cardioverter-defibrillator) was implanted. In 
the family history two siblings (brother and sister) suddenly died at 2- and 
3-years old respectively, even if they were completely asymptomatic. He 
has other two sisters (6- and 7-years old) and 1 brother (1-year old), who 
are alive with no symptoms until now. Their parents are healthy. The 
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proband's clinical phenotype is not clear and it was not possible to define 
his clinical diagnosis because of the presence of an atypical 
electrocardiogram pattern and a high recurrence of episodes of ventricular 
fibrillations (Figure 15). 
 
Figure 15 Complete family tree. Arrows indicate the samples sequenced by 
whole-exome sequencing 
2.2.2. Whole-exome sequencing 
Whole-exome capture and library preparation was performed using the 
Agilent SureSelect
XT 
Human All Exon 50Mb kit (Agilent Technologies, 
Santa Clara, CA, USA), according to the SureSelect
XT 
Target Enrichment 
System for Illumina Paired-End Sequencing Library protocol (version 1.1.1; 
Agilent Technologies). Briefly, 3 ug of genomic DNA per sample were 
sheared using a Covaris S2 AFA instrument (Covaris, Woburn, MA, USA) 
to a target peak size of 150-200 bp. After fragmentation check by Agilent 
2100 BioAnalyzer microcapillary electrophoresis (Agilent Technologies), 
the exome capture protocol was performed according to manufacturer’s 
instructions and included genomic DNA library preparation and then target 
enrichment by using Agilent SureSelect exome capture baits. Finally, post-
	   34	  
capture libraries were loaded, one sample per lane, onto the Illumina cBot 
Cluster Generation System (Illumina, San Diego, CA, USA) at a 8 pM final 
concentration, and then sequenced by Illumina GAIIx instrument, in a 
paired-end 85-cycle run. For raw data processing, the Sequencing Control 
Software (SCS, Illumina) was used to convert raw image data into qseq 
files and then CASAVA software (Illumina) to generate final fastq files. 
 
2.3. Bioinformatics data analysis 
2.3.1. Quality assessment and Mapping  
Paired-end reads were mapped against the NCBI human reference 
genome GRCh37 build using BWA [32] with default parameters. BWA is a 
tool for mapping raw reads to the reference sequence and its algorithm is 
based on backward search with Burrows-Wheeler Transform (BWT), to 
efficiently align reads against a reference sequence, allowing mismatches 
and gaps. 
Briefly, all the reads with more than 5 mismatches or those with mapping 
quality (MAPQ) less than 15 were filtered out. The MAPQ score is very 
important in short read aligning because indicates the probability of each 
mapped read to be misplaced. The score is subsequently transformed in 
log scale. Afterward, we removed duplicate reads due to clonal 
amplification during library preparation in order to avoid allele frequency 
errors and we converted them into standard BAM file, using SAMtools (v. 
0.1.12a) [34] obtaining an high-quality alignment (HQ) file for each sample. 
All the mapping statistics were performed on HQ-mapping files using in-
house scripts including calculation of the percentage of read mapping the 
human genome, calculation of target/exome coverage, calculation of read 
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mean depth for every sample and calculation of not-covered regions due to 
technical issues. 
2.3.2. Genotype call 
Mutations discovery were performed using GATK software [37] that use a 
Bayesian genotype likelihood model to estimate simultaneously the most 
likely genotypes and allele frequency in a population of 91 samples, 
emitting an accurate posterior probability of there being a segregating 
variant allele at each locus as well as for the genotype of each sample. 
This method greatly improves the specificity of the calls and reduces the 
false positive SNV calls. 
Briefly, HQ-mapping files were used for single nucleotide variation and 
insertion/deletion analysis using GATK software (v.2.1-9), with the following 
procedure: (a) reads were recalibrated using TableRecalibration walker to 
bring quality scores closer to their actual probability of mismatching the 
reference genome; (b) reads were realigned around known indels using 
IndelRealigner walker and the 1000 Genomes Project data 
(http://www.1000genomes.org) in order to improve the alignment quality on 
regions with known INDEL data; (c) the UnifiedGenotyper walker was used 
to perform SNV/INDEL calling, thus generating a Variant Calling Format 
(VCF) file containing all the raw variations detected for each sample; (d) 
groups of three SNVs within 10 base-windows were flagged as 
“SNPCluster” in the FILTER field of the VCF file. 
2.3.3. Mutation filtering 
The analysis part of mutation filtering is the key point to ensure the 
reliability and the strength for mutation data. Applying stringent criteria as 
heuristic filters on sequencing data like minimum sequencing depth or 
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strand bias evaluation is the best way to eliminate the maximum number of 
false positive calls.  
To select very confident and high-quality single nucleotide mutations (HQ-
SNV) and INDEL mutations (HQ-INDEL), a series of filtering options were 
applied for further analyses. The filtering criteria were: (i) minimum read 
depth of 15x; (ii) variation quality score above 150 and (iii) non-reference 
allele frequency above 20%. Other GATK specific filters, such as strand 
bias (FS), HaplotypeScore, ReadPosRankSum and Quality by Depth (QD) 
were applied following the GATK Best Practice v4 (http://bit.ly/13ffAtu).  
Afterwards, only those variations on the coding regions were selected. 
A good way to narrow down the number of possible mutations in 
exome/target sequencing project is to eliminate those variants already 
known as polymorphisms in public database. Indeed, to create a subset of 
novel variations, those not already reported as known polymorphism in 
1000 Genome Project (Phase I) [35] or in dbSNP v137, were selected and 
classified as novel coding HQ-SNVs and novel coding HQ-INDELs. After 
that, HQ variants were classified and divided into functional category such 
as silent (synonymous), missense (non-synonymous), nonsense (stop 
codon) or splice site for HQ-SNVs and frame-shift, codon insertion or 
codon deletion for HQ-INDELs. Synonymous HQ-SNVs were subsequently 
ignored creating a subset of novel possibly deleterious HQ-SNVs (NS-
SNV) (Figure 16). 
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Figure 16 Bioinformatics analysis workflow for target sequencing projects. 
The sequencing reads of the 91 BrS patients have been mapped against human 
genome reference and the low quality reads were discarded. After the variation call 
performed by sample, the detected variations have been annotated and filtered by 
quality. The HQ-variations have been categorized into three category: Clinical rs 
variations (based on dbSNP annotation), Novel Coding NS-SNV containing the 
novel deleterious single nucleotide variations and Novel Coding HQ-INDEL 
including the novel coding insertion or deletions found within the samples. 
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2.3.4. Variant annotation and variant quality filtration 
Raw variants, known as polymorphisms, were annotated using the 
VariantFiltration walker in GATK, according to dbSNP v137, 1000genomes 
data and Exome Sequencing Project (ESP) variations database 
(http://evs.gs.washington.edu/EVS/). The use of the 1000genomes and 
ESP databases as resources is very important to evaluate the allele 
frequency in the human population compared to variants found in our 
samples. Particularly, the 1000genomes project calculated an estimation of 
the variations within the healthy human population by generating a value 
called minor allele frequency (MAF) for every SNV found in their dataset. 
On the other hand, the ESP database calculated in the same way the MAF 
value but the 6500 exomes analysed till now, were not collected as healthy 
samples. That information is fundamental in order to filter-out or annotate a 
particular variant found in those resources. Variations with known clinical 
significance were annotated and treated separately. 
Gene locus annotation and amino acid variation were generated using 
SNPEff [40] considering only protein-coding transcripts. Non-synonymous 
SNVs were subsequently annotated with PolyPhen2 [72], SIFT [58] and 
Mutation Taster for pathogenicity prediction and with GERP++ [56] for 
conservation score. Pathogenicity prediction annotation and conservation 
score were computed using SNPSift [104] in combination with dbNSFP 
v(2.0b3) [60] as described in 
http://snpeff.sourceforge.net/SnpSift.html#dbNSFP 
2.3.5. Statistical analysis with 1000 Genomes data 
Mutation data from 1000 Genomes Project has been downloaded and used 
for mutation comparison in Case 1 study. Briefly all the chromosomes raw 
VCF files containing all the integrated call set phase 1 v3 were selected 
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and downloaded from ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/. The integrated call 
set contained all the variations present in the 1000 Genomes samples 
produced by genome and exome sequencing. The variations were 
annotated with VariantAnnotator walker (GATK 2.5-2) by using the 
annotation file 
(ALL.wgs.integrated_phase1_release_v3_coding_annotation.20101123.sn
ps_indels.sites.vcf.gz) contained into the 1000 Genomes Project FTP site. 
Afterward only the 379 European (EUR) samples were selected in order to 
evaluate the most comparable mutational rate with our cohort. The 
description of the selected population is available at 
http://www.1000genomes.org/category/frequently-asked-
questions/population. SNV and INDEL variations occurring in target region 
genes were extracted and selected those variations annotated as coding, 
non-synonymous narrowing the focus to those variations called by just 
exome data or confirmed by both genome and exome sequencing data. 
To generate a random dataset of the 379 European samples comparable to 
the Brugada cohort in Case 1, 50 permutations of 91 samples were 
performed to calculate the number of rare variations (found at least in two 
individuals) for each subsampling and for every target gene. This dataset 
were used to draw a distribution of mutation rate of 91 healthy controls and 
to compare the mutational rate of every gene normalized by gene length 
with the 91 Brugada patients of Case 1. 
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3. RESULTS AND DISCUSSION 
3.1. Case 1: Target sequencing of 91 Brugada patients 
3.1.1. Target Sequencing Statistics 
We designed a custom Agilent capture system in order to analyse all the 
coding exons of 158 selected genes in our cohort of 91 patients. Each 
sample capture was followed by sequencing on Illumina GAIIx, generating 
an average 10,833,247 +/- 7,419,828 mapped reads (Table 1). 
 
Table 1 NGS sequencing statistics of 91 Brugada samples. Summary of the 
sequencing performance across the 91 Brugada samples represented by the 
number of read generated (Raw reads), the number of the reads actually mapped 
against the Human genome (Mapped Reads), the number of reads, on average, 
that covered the target region (Depth) and the percentage of target region covered 
by at least 1 read (Coverage, 1X) and by at least 15 reads (Coverage, 15X). 
An automatic pipeline for data analysis was developed in order to facilitate 
the analysis steps and to standardize the results for each sample. 
After duplicate removal and low-quality reads filtering, we obtained a mean 
target coverage of 99.16% +/- 1.06 (Figure 17) with a mean sequencing 
depth of 327.22x +/- 137.35 among the samples. Moreover, thanks to the 
high-sequencing depth obtained, we had a 92.94% +/- 9.78 of the covered 
regions supported by at least 15 reads, which is the minimum read depth 
for SNVs.  
Mean +/- SD Median 1st quartile 3rd quartile 
Raw Reads 11,188,822 +/-  7,802,174 9,379,338 7,733,175 11,006,395 
Mapped Reads 10,833,247 +/- 7,419,828 9,127,572 7,479,202 10,680,006 
Depth (fold) 327.22 +/- 137.35 334.20 243.46 411.46 
Coverage (%) 
  1X 99.16 +/- 1.06 99.44 99.30 99.54 
  15X 92.94 +/- 9.78 95.18 94.01 96.11 
S quencing summary statistics 
91 samples 
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Figure 17 Target region coverage by incremental depth. Boxplot representing 
the target coverage distribution across the 91 Brugada samples (y-axis) 
considering different read depth (x-axis). 
Overall, we found 118,388 SNVs and 14,590 INDELs, with an average of 
1461 variations per sample and 273 variations per sample considering only 
those annotated in coding regions (range: 98 to 310). In order to select and 
prioritize candidate mutations, we filtered out all variations already known 
as polymorphisms within the human population as well as variations 
present in non-coding regions, narrowing down to 158 variants with an 
average 1.7±1.43/patient.  
We further classified this filtered variations dataset in three categories: 
novel NS-SNVs possibly affecting protein function (missense, nonsense 
and splice-site variations), clinical-rs variants previously reported in dbSNP 
v137 and novel coding INDELs. In particular, we identified 85 NS-SNVs, 60 
clinical-rs variations and 13 novel coding HQ-INDELs (section 6.1.3, 6.1.4, 
6.1.5). 
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3.1.2. Novel variations  
82 out of the 85 NS-SNVs were missense substitutions, 2 were predicted to 
alter canonical donor splice sites, respectively on KCNJ15 and SCN10A 
genes, and only 1 variant in NRG1 was reported as nonsense. We decided 
to sequence by Sanger sequencing the lowest covered mutations (with 
depth < 30X) to exclude the presence of false positive calls introduced by 
the variant calling system and filtration. All the 9 NS-SNVs below the 30X 
coverage threshold were confirmed by Sanger sequencing, indicating a 
robust calling method and quality filtration. 
All the NS-SNVs variants were identified in a total of 53 genes and private, 
with the exception of one missense variant (Ensembl transcript ID 
ENST00000361308:c.599A>G; p.K117R) in the LMNA gene, identified in 
two BrS patients of our cohort. 
In the analysis of the 84 private variants, we found several recurrent genes. 
In particular, ANK2 and ANK3 genes, coding for ankyrin proteins, 
presented respectively 5 and 4 missense substitutions, and CACNA1H 
gene, encoding the calcium voltage gated channel, harboured 5 NS-SNVs 
(Figure 18) 
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Figure 18 Most mutated genes in novel variations category. Gene mutations 
count distribution (descending order). Red bar showed the number of mutations 
predicted to be damaging by at least two out of three bioinformatics tools. Green 
bar showed the number of mutations with low pathogenicity value (predicted to be 
neutral) 
In silico pathogenicity analysis revealed that 31 genes carried one variation 
with a potential pathogenic impact and 12 carried two: voltage-gated 
sodium channels and their interacting proteins (SCN1A, SCN4A, SCN11A, 
ANK3 and SNTG2), voltage-gated calcium channels (CACNA1E and 
CACNA1H), ligand-gated channels (NRG1 and SLC6A4), genes previously 
involved in cardiomyopathies (MYH6 and LMNA) and RYR2 encoding 
ryanodine receptor. These putative pathogenic variants were present in 38 
patients, and in half of them (19/38) these were not associated to other 
pathogenic variations (either novel or clinical-rs). 
Among the 13 novel HQ-INDEL variations identified in 11 patients, 8 were 
deletions and 5 insertions. The deletion detected in KCNK17 gene and the 
insertion in CLCN2 occurred twice in different patients. Six variations were 
classified as frameshift with possible dramatic change in protein translation, 
including two found in the same patient affecting AGTR1 and SCL6A4 
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genes. The remaining four frameshift variations were private and involved 
CHRNB2, MYH6, SCN11A and KCNC3 genes. 
3.1.3. Clinical-rs variations 
We also identified 60 SNVs previously described in dbSNP v137 and, 
although they were flagged as clinically associated, only a minority was 
defined as clearly pathogenic. Those particular variants have been 
previously associated to particular diseases in dbSNP database. 
Indeed, 31 out of 60 were missense variations and only 10 of them had 
been marked as pathogenic: rs72544141 and rs121912706 in ANK2 and 
rs74315448 in KCNC3 had been previously described in cases of Long QT 
Syndrome (LQTS); rs121913013 in DSG2 and rs121912998 in DSP had 
been associated with ARVD; rs45454496 in ANK2 had been linked to a 
cardiac arrhythmia syndrome; rs121917810 in AGTR2 and rs121434525 in 
ACTN2 had been associated with cardiomyopathy; rs121908919 in SCN9A 
had been described as pathogenic in epilepsy and rs1800888 in ADRB2 
associated with an ischemic heart disease. All these clinical-rs were private 
in our cohort of patients with the exception of rs45454496 and 
rs121912998 that were identified in two patients, and rs1800888, present in 
three different patients. 
We analysed pathogenicity of all the other clinical-rs coding variations 
classified as “untested”, “other” or “probably non pathogenic” in dbSNP 
v137, by using bioinformatics prediction and conservation tools as 
described in Methods. According to our criteria three of them, rs121918769 
in SCN1A, rs141423405 in KCNE2 and rs71318369 in CLCN2, were 
considered probably damaging. The clinical rs141423405 had been 
previously reported in a case of LQTS, corroborating the hypothesis that 
this variant might have a pathogenic role in arrhythmogenic mechanisms.  
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In addition, five patients were affected by the same missense variant 
(rs41280102) in the SCN4A gene, which is the most recurrent missense 
variant in our cohort (5.5% frequency). Although this variant was reported 
as non-pathogenic in dbSNP v137 but untested, it was significantly over-
represented in our cohort compared to 1000 Genomes allele frequency 
(P<0.05; Fisher Test). 
3.1.4. Permutation analysis with 1000 Genomes data 
To verify the robustness of the genes choice, the overall mutations found in 
the 91 Brugada patients was compared to random permutations of 91 
healthy control samples coming from the EUR population of the 1000 
Genomes Project. Considering only the NS-SNVs called in our cohort, the 
overall count (85 mutations) was clearly higher the non-synonymous rare 
mutations present in 1000 Genomes data (55.94 +/- 6.9) suggesting a real 
involvement of those genes in BrS development (P-value<0.01) (Figure 
19). 
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Figure 19 1000 Genomes variations distribution compared to Brugada 
Samples. Representation of the cumulative mutations, among the 70 genes 
mutated in the Brugada samples, applying 50 random sampling of 91 individuals 
from the 1000 Genomes data. The blue dotted vertical line indicates the number of 
mutations found in our cohort. 
Moreover, to examine in depth the significance of the mutations, to better 
classify the mutated genes and to prioritize them in relationship with BrS, 
we compared the mutational rate of the most recurrent mutated genes (two 
or more mutations found in our cohort) with the mutational rate of those 
genes in a healthy control dataset as the 1000 Genomes Project data 
(Figure 20).  
Pr
ob
ab
ilit
y d
en
sit
y
30 40 50 60 70 80 90
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
0.
07
Number of mutations
	   47	  
 
Figure 20 Mutation rate comparison of recurrent mutated genes in Brugada 
samples against 1000 Genomes. Evaluation of the mutational rate (number of 
mutation per kilobase) for recurrent genes (at least 2 mutations across all samples) 
found in our cohort in comparison to variation found in 1000 Genomes data. Yellow 
circles indicate the average mutational rate in 1000 Genomes. Red circles indicate 
the mutational rate found in Brugada samples Y-axis indicates the -log10 of P-
values, grey dotted line represents the 0.05 significance threshold). 
This analysis revealed that a few genes with high number of mutations in 
our cohort, including ANK3, CACNA1H, MYH6, were affected by the same 
mutational rate (P-value>0.05) as in the 1000 Genomes data actually 
decreasing the strength and the involvement of those genes in the disease. 
On the other hand, we found 13 genes were strongly mutated compared 
with the mutational rate in the 1000 Genomes data (P-value<0.05, -log10P-
value>1.3). Among all the statistically significant genes the most relevant 
ones for the biological function were RYR2, which was never been 
associated to BrS, and two genes encoding for calcium channels such as 
CACNA2D2 and CACNA1E. 
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3.1.5. Downstream analysis and mutations discussion 
Candidate BrS genes were evaluated based on two main criteria: 
frequency of variations in our cohort and their predicted in silico 
pathogenicity. These results suggested several new candidate genes with 
a possible involvement in the pathogenesis of BrS. Overall, possibly 
pathogenic NS-SNVs were detected in 38 patients and in half of them this 
was the only pathogenic variation identified, suggesting a causative 
association with the disease. 
The most mutated gene in our cohort was RYR2, encoding ryanodine 
receptor and previously associated to ARVD and catecholaminergic 
polymorphic ventricular tachycardia (CPVT), where it has a principal role in 
mechanisms underlying triggered arrhythmias [105]. In this gene we 
identified 7 clinical-rs, classified in dbSNP v137 as probably non-
pathogenic, consisting of non-coding and synonymous variants. In addition, 
we detected 3 private NS-SNVs, including 2 with a high pathogenic effect 
predicted by bioinformatics tools. RYR2 had never been associated with 
BrS until now and we might thus hypothesize a role in this syndrome and in 
addition it was never seen mutated in all the 50 sampling permutation of 
1000 Genomes mutation data. 
Our data also confirms the overlap of clinical phenotypes reported in some 
BrS and ARVD patients [106, 107]. Indeed, besides RYR2, our study 
detected several variants in genes associated with different types of ARVD, 
such as DSG2, DSP and TGFB3, suggesting a common genetic 
background in the arrhythmogenic mechanism in these different 
pathologies. 
The sodium channel family was the most mutated in our study considering 
clinical-rs and NS-SNVs. Influx of sodium ions through cardiac voltage-
gated sodium channels is responsible for the initial fast upstroke of the 
cardiac action potential, thereby triggering the initiation and propagation of 
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action potentials throughout the myocardium [108]. Cardiac sodium 
channels thus play an essential role in excitability of cardiac cells and 
proper conduction of the electrical impulse within the heart and, although 
SCN5A gene is the principal causative gene in BrS, we may assume that 
also other types of voltage-gated sodium channels may be involved in 
arrhythmogenic mechanisms. In particular, we identified possibly 
pathogenic variants in SCN1A, SCN2A, SCN4A, SCN8A, SCN9A, SCN10A 
and SCN11A genes in 15 patients out of 91 (nearly 17%). 
Although when BrS was described for the first time in 1992 it was 
associated to a loss of function of the SCN5A gene, it was later 
demonstrated an important role for other voltage-gated ion channels in BrS 
pathogenesis. Indeed, to date, several potassium channels have been 
associated with BrS, such as KCNE3 [MIM: 604433] (BrS6), KCNH2 [MIM: 
152427] (BrS8), KCNE2 [MIM: 603796] (BrS9), KCNJ8 [MIM: 600935] 
(BrS10), KCNE5 [MIM: 300328] (BrS13) and KCND3 [MIM: 605411] 
(BrS14) [109]. 
Our results suggest an important pathogenic role for other potassium 
channels that were recurrently mutated in our cohort; for example missense 
pathogenic variants were detected in KCNA2, KCNA7 and KCNS3 [MIM: 
603888] genes, which are expressed in cardiac cells and responsible for 
the delayed rectifier current and one splice site variants was identified in 
KCNJ15, encoding the inwardly rectifying potassium channel. Notably, 16 
patients out of 91 (nearly 17%) harboured mutations in potassium 
channels. 
Mutations localized in cardiac L-type calcium channels had been clearly 
associated with typical BrS ECG pattern and the development of 
polymorphic VT, that can lead to SCD [110], but until now the protein 
Cav1.2, encoded by CACNA1C gene, was the only alpha subunit of cardiac 
L-type calcium channel associated with BrS (BrS3) [109]. Our analysis 
suggests a possible pathogenic role also for cardiac Cav3.1 and Cav 3.2 
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alpha subunits of calcium channel encoded by CACNA1G and CACNA1H 
genes, in which we detected respectively 1 and 2 probably pathogenic 
novel missense variants. In addition, the alpha-2/delta subunit of calcium 
channel is encoded by at least 4 different genes and one of them, 
CACNA2D1, is already annotated in literature as a BrS susceptibility gene 
[111]. Our study identified 3 novel missense variants in CACNA2D2, 
encoding alpha2/delta2 subunit of calcium channel expressed in heart and 
one of these NS-SNVs was predicted as pathogenic and it was the gene 
with the stronger mutational rate difference between our cohort and the 
1000 Genomes samples. In our study we identified 7 mutations carriers out 
of 91 patients in these 3 genes (8%). We can therefore hypothesize the 
involvement of other types of alpha-2/delta subunit of calcium channel in 
BrS pathogenesis. 
A gene carrying several novel variations in our cohort is ANK2 encoding 
ankyrin-B, an adapter protein whose genetic variants have been previously 
associated with arrhythmic susceptibility. Indeed, in this gene we detected 
3 clinical rs (rs45454496, rs72544141 and rs121912706) previously 
described in literature in clinical cases of arrhythmogenic disease and 
LQTS [112]. It is known that several genetic variants can be implicated both 
in LQTS and BrS, so we may suggest a possible implication of these 
clinical rs in BrS pathogenesis. Moreover, in one patient we detected the 
clinical rs66785829 in ANK2, previously described in a patient with typical 
ECG type I [113], corroborating the idea of a causative role of ANK2 in BrS 
pathogenesis. ANK2 is also the most mutated gene considering NS-SNVs, 
leading us to hypothesize that also the 5 novel missense substitutions 
detected in our cohort might have a causative role in BrS phenotype. 
Another interesting candidate gene may be ANK3, encoding ankyrin-G 
isoform, in which our target sequencing detected 4 NS-SNVs in 4 different 
BrS patients. It has been shown that ankyrin-G is associated with the 
cardiac sodium channel and that, like Nav 1.5, it is highly expressed in 
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cardiomyocytes. Moreover, a human mutation in the SCN5A gene was 
described to block ankyrin-G binding, affecting the expression of Nav 1.5 in 
the cardiomyocytes membrane and resulting in BrS phenotype [114], 
suggesting the pathogenic role of ankyrins in BrS with 14 out of 91 (15%) 
patients harbouring mutations.  
NRG1 is another gene that may be associated with BrS phenotype, 
carrying 3 novel variants, 2 of them predicted as damaging by our in silico 
analysis. Neuregulins are important for maintenance of acetylcholine 
receptor-inducing activity of nicotine receptors in neurons, skeletal muscle 
and in the heart where the parasympathetic activation counterbalances β-
adrenergic activation [115]. Indeed, it is known that the magnitude of ST-
segment elevation can be reduced by adrenergic agonists, whereas it is 
increased by parasympathetic agonists or adrenergic antagonists [116, 
117]. 
The putative role of the nervous system in arrhythmia induction is 
confirmed also by the role of Nav1.8 channel, encoded by SCN10A gene, 
that is highly expressed in neurons of dorsal root ganglia and cranial 
sensory ganglia and described by several genome-wide association studies 
as a modulator of cardiac electrophysiology [46]. Nav 1.8 based sodium 
channels are absent in cardiomyocytes but are present in the intracardiac 
neurons of murine heart and a pharmacologically blockade of this channel 
may influence the properties of the neural activity[118]. In particular, 
SCN10A expression contributes to late sodium current in heart and 
represents a new target for antiarrhythmic intervention [119]. 
BrS was originally considered an electrical disorder occurring in the 
absence of structural heart disease, and the presence of myocardial 
abnormalities in these disorders was excluded by definition. However, 
another interesting data emerging from our study is the presence of novel 
variants with a probable pathogenic impact in MYH6 and MYH7, encoding 
the alpha- and beta-myosin cardiac heavy chain, respectively, and involved 
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in different cardiomyopathies. Indeed, several studies already showed that 
sodium channel dysfunction may result in structural abnormalities in the 
myocardium, even if the pathological mechanisms possibly involved have 
still to be clarified [92, 120].  
Interestingly all the detected novel variations are private with exception of 
the missense variant p.K117R (Ensembl transcript ID 
ENST00000361308:c.599A>G; p.K117R) identified in the LMNA gene, 
encoding lamin A/C, in two BrS patients of our cohort. Also LMNA gene 
had never been involved in BrS, however it has been associated with more 
than 10 different clinical phenotypes, including cardiac abnormalities 
characterized by atrial fibrillation, conduction-system disturbances, dilated 
cardiomyopathy, sudden death and heart failure [121, 122]. Carriers of 
lamin A/C mutations can develop VTs with progressive conduction block 
and sinus block requiring ICD therapy for efficacious primary prevention 
[123]. It may be therefore important to investigate the possible causative 
role of LMNA mutations in ventricular instability in BrS patients. 
Moreover to better understand genotype-phenotype correlation, we 
performed an enrichment analysis of the most mutated genes of our panel, 
classified by functional category. We also divided patients in classes 
according to three phenotype traits such as ECG type I, Flecainide positive 
and Sudden death familiarity.  
Considering the patients of our cohort with a family history for SD (29%), 
the most mutated genes encode calmoduline and this functional 
enrichment is statistically significant (P-value<0.05; Fisher Test) (Figure 
21). 
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Figure 21 Genes functional enrichment considering to Brugada phenotype: Genes 
of the target were divided into functional category based on the protein function. 
Genes mutated in patients (red bars) were compared to the percentage (x-axis) of 
genes within the target list (blue bars). The Calmoduline gene family resulted 
statistically enriched in patients with sudden death familiarity (panel A). Whereas 
the Sodium channel family resulted enriched in patients belonging to type I ECG 
and Flecainide positive category (panel B). Stars (*) indicate P-value<0.05 for 
Fisher Exact test. 
Interestingly, grouping the samples with spontaneous type I ECG and those 
patients with a type I ECG induced by Flecainide, the most mutated class 
of genes is the Sodium channel (P-value<0.05; Fisher Test). This result 
suggests and confirms the essential role of the sodium channel family in 
relationship with the BrS onset. 
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In conclusion, this study identified new several candidate genes associated 
with BrS ECG. In order to better evaluate their contribution, it will be 
important to combine genetic studies with molecular and functional 
experiments that will help identify and prioritize novel genes and pathways 
potentially relevant for cardiac electrophysiology [124, 125]. In addition, 
intra-familial segregation studies will be necessary to correlate the role of 
putative pathogenic variants to the pathological phenotype. Notably, since 
20 BrS patients of our cohort were not mutated in any gene of the selected 
panel, we plan to perform in these cases an exome-sequencing to identify 
new putative causative genes. These studies may provide new targets for 
genetic screening and future development of therapeutic strategies [90]. 
Ultimately, these combined clinical, genetic and translational studies should 
lead to improved diagnosis, risk stratification, treatment and outcome in 
patients with diagnosis of BrS. 
 
3.2. Case 2: Whole-exome sequencing of family trio samples 
3.2.1. Whole-exome sequencing statistics 
We performed a paired-end sequencing for each sample of the family 
producing an average of ≈ 175 million of reads. To ensure the maximum 
reliability and robustness for mutation analysis, we performed at least two 
runs to reach the minimum exome coverage of 94.19% with a minimum 
mean depth of 87.15X for each sample (Table 2). 
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Table 2 Exome sequencing statistics of trio samples. Summary of the 
sequencing performance for all the trio samples indicated by the number of read 
generated (raw reads), the number of the reads actually mapped against the 
Human genome with their percentage related to the reads produced (mapped 
reads), the number of reads, on average, that covered the exome region (depth) 
and the percentage of exome region covered by at least 1 read (coverage, 1X) and 
by at least 15 reads (coverage, 15X). 
We obtained that more than the 85% of the entire target was covered by at 
least 15 reads, which is the minimum read depth for SNV calling, indicating 
a robust and reliable coverage to evaluate variations in the majority of the 
target. The statistics for sequencing quality check are essential for the trio 
analysis because only those positions overlapping the three samples are 
eligible for the mutation call analysis, the non-overlapping ones were not 
considered for further analysis. After quality control and mutation calling, all 
the variations found in all the three samples were analysed by just 
considering SNVs.  
3.2.2. Trio analysis 
The big advantage of trios analysis is the opportunity to retrace the 
inherited mutations found in the disease-affected sample back to the 
parents and to clearly identify de novo mutations occurred in the affected 
sample by analysing Mendelian violations. 
We found a mean of 39,147.6 SNVs across the samples considering the 
exome region captured (Table 3).  
112252 (Child) 112315 (Mother) 112316 (Father) 
Raw reads 127,090,729 212,210,584 185,347,716 
Mapped reads (%) 75,100,902 (59.09) 188,083,331 (88.63) 164,272,934 (88.62) 
Mean depth (fold) 87.51 186.05 166.73 
Coverage (%) 
      1X 94.19 96.63 96.09 
      15X 85.81 91.67 90.73 
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Table 3 Mutations annotations and filtration. After SNV calling, variations were 
reported and annotated to evaluate their strength in disease onset. The raw calls 
(No. sites overall) were filtered by quality parameters described in Materials and 
Methods section. High-quality variations (quality passed sites) were further filtered 
by eliminating those variations known as polymorphisms within the population 
according to 1000 Genomes and dbSNP v137 data. The resulting novel variations 
(novel variations) were annotated by considering the coding region and divided into 
4 categories (synonymous, non-synonymous, nonsense, splice-site). 
For better evaluate those variations with a possible involvement to the 
disease, we filtered out the variation occurred in non-coding region as well 
as those annotated as synonymous SNVs which does not change the 
protein sequence. Moreover all the SNVs present into human variation 
databases such as 1000 Genomes and dbSNP v137, were considered as 
polymorphisms within the healthy human population and therefore were 
excluded from further analysis. 
In this particular case, considering the rarity of the disease, the hypothesis 
was to find homozygous mutations in the child, the affected sample, which 
could explain the severe arrhythmogenic disease not present in the 
parents. Indeed on one side, the homozygous mutations in the child were 
evaluated in order to select candidate mutations related to the disease, 
secondly the de novo mutations were extracted by subtracting the 
variations found in the parent sample. 
112252 (Child) 112315 (Mother) 112316 (Father) 
No. sites overall 37,828 40,353 39,262 
Quality passed sites 32,668 36,541 35,329 
Novel mutations 771 928 883 
Coding mutations 395 486 450 
  Synonymous 173 201 173 
  Non-synonymous 213 271 267 
  Nonsense 6 7 7 
  Splice site sites 3 7 3 
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Considering the 222 novel possible deleterious mutations (non-
synonymous, nonsense and splice-site categories) found in the child, only 
six occurred as homozygous and therefore were investigated as potential 
candidate mutations (Table 4). Although all the mutations were predicted 
by at least one bioinformatics tool to be dangerous for the related protein, 
two of those occurred in genes that were already associated to 
arrhythmogenic disease. 
 
Table 4 Six novel candidate homozygous mutations. Novel possible deleterious 
mutations were reported. All the missense mutations were also evaluated by three 
different bioinformatics tools (MutationTaster, Polyphen2, SIFT). Mutattion Taster 
and Polyphen2 score description: D=Damaging, B=Benign, N=Neutral, P=Probably 
damaging. SIFT score description: score<0.05 indicates damaging prediction 
otherwise benign prediction. 
In particular UNC45A encodes for a chaperone protein that is involved in 
cell proliferation and myoblast fusion by binding progesterone receptor and 
acts as regulator within the progesterone receptor chaperoning pathway 
[126, 127]. The mutation found was predicted by 2 out of three 
bioinformatics tools a damaging mutation that could influence the 
functionality of the protein. Knockdown of UNC45A in Drosophila 
melanogaster results in a reduced beat rate as well as reduced cardiac 
contractility suggesting a key role in heart activity [128]. 
Another interesting mutation was the p.L56P occurred in the TRDN gene. 
This gene, encoding for an integral membrane protein named triadin, is 
strictly involved in excitation-contraction coupling as part of calcium release 
complex in association with ryanodine receptor (RYR2). Mutations in TRDN 
gene have been found in catecholaminergic polymorphic ventricular 
Chr Pos Ref Alt AA-change Mutation-type Gene-name MutationTaster Polyphen2 SIFT
6 123892133 A G L56P MISSENSE TRDN H D 0
11 118531346 G A S212L MISSENSE TREH N B 0.16
11 125453602 G A G48R MISSENSE EI24 H H 0
15 91491962 G A D591N MISSENSE UNC45A D D 0.49
16 68011241 A G I342T MISSENSE DPEP3 D B 0
22 39032562 T C Y132C MISSENSE RP1H199H16.5 N P 0.02
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tachycardia (CPVT) [129] characterized by bi-directional ventricular 
tachycardia that may degenerate into cardiac arrest causing sudden death. 
In particular, p.T59R mutant of triadin protein in mice resulted in instability 
of the protein leading to its degradation. The homozygous mutation found 
in our affected sample share the same protein domain and could suggest 
the same behaviour of the T59R mutant triadin and including this mutation 
in the candidate list. Obviously, further functional analysis needs to confirm 
the absence of the triadin protein and therefore its implication in the 
disease onset. 
To classify the strength of the candidate mutations, segregation study has 
been performed among relatives (Figure 22). Using Sanger sequencing 
validation we confirmed the six heterozygous mutations in the parents and 
we found that all the six homozygous mutations were heterozygous in the 
two unaffected sisters and in the one unaffected brother. 
 
Figure 22 TRDN and UNC45A segregation analysis. Family tree indicating 
genotype information about the candidate mutations found in the proband. The 
colours highlight the genotype status of the mutations, green boxes indicate the 
heterozygous status, yellow boxes indicate the homozygous status and no colour 
is for the wild type genotype. 
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The segregation analysis was not able to identify which of the six mutations 
could be the driving one for the pathology. Therefore functional studies are 
needed to clearly correlate the mutations with the disease and to confirm 
their pathogenic role. 
De novo mutations were also evaluated in the patient to expand the 
mutation analysis. We found that two novel non-synonymous mutations 
were present all in heterozygous status (Table 5). 
 
Table 5 De novo mutation in affected sample. Novel coding mutation not 
present in parents (de novo mutations) were reported. All the missense mutations 
were also evaluated by three different bioinformatics tools (MutationTaster, 
Polyphen2, SIFT). D=Damaging, B=Benign, N=Neutral, P=Probably damaging. 
SIFT: score<0.05 indicates damaging prediction otherwise benign prediction. 
The most relevant variation was the one occurred in the MFHAS1 gene. 
The protein structure is characterized by three leucine zipper domains, and 
a leucine-rich tandem repeat, which are structural or functional elements for 
interactions among proteins related to the cell cycle. 
Although this protein is not correlated to any cardiac disease, it is well 
known that the overexpression of its transcript is particularly associated to 
malignant fibrous histiocytoma (MFH) onset [130]. 
Chr Pos Ref Alt AA-Change Mutation-type Gene-name MutationTaster Polyphen2 SIFT
8 8748608 T C N654S MISSENSE MFHAS1 D D 0.7
19 4512964 G A T322 SILENT PLIN4 L L L
19 4512979 T A T317 SILENT PLIN4 L L L
19 12015991 C G S260C MISSENSE ZNF69 L L 0.2
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4. CONCLUSION AND FUTURE PERSPECTIVES 
The very last part of this PhD dissertation summarises the results obtained 
in the research projects and suggests future perspectives for further 
investigations. 
For the first project, we performed a target sequencing of 158-selected 
gene in a cohort of 91 Brugada patients. Since the 30% of BrS cases are 
associated to SCN5A mutations, the remaining 70% are still without a 
genetic explanation. Therefore we accurately selected a set of 158 genes, 
mainly belonging to ion channel category, previously associated to 
arrhythmogenic diseases. We collected and sequenced, for this gene panel 
set, 91 BrS samples with no disease-causing mutations in the SCN5A 
gene. 
Two important results have been achieved from this research project: 
1) We tested and developed an automated pipeline for NGS data 
analysis involving gene panel sequencing project. In particular 
two main aspects are notable: (1) the use of completely free 
available tools for each analysis module and (2) the sensitivity 
of the variant call system which was confirmed by other 
techniques (Sanger sequencing). 
2) We found a set of mutated genes previously not associated to 
BrS thanks to a statistical validation with 1000 Genomes project 
data. 
In the next future we will implement the pipeline as a free-available 
package able to perform the complete bioinformatics analysis from raw 
reads to variant calls and functional annotations. Moreover, we will perform 
functional analysis of few selected mutations of candidate genes to 
evaluate the possible damage caused by the mutations. Furthermore we 
will plan to test novel candidate genes coming from this analysis on a larger 
dataset in order to better estimate the genetic risk of BrS. 
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The second study was applied to the whole-exome sequencing of a family 
trio where the child is affected by an unclear cardiac disease with an 
atypical electrocardiogram pattern. Because of the unclear diagnosis the 
use of whole-exome sequencing technology was the optimal and cost-
effective solution to widely screening all the coding regions of the genome 
in a shot. Thanks to the approach of trio sequencing, the candidate variants 
were filtered by subtracting the germline mutations found in the parents 
samples. Moreover, because of the severe episodes of cardiac arrest, we 
focused our attention on the homozygous mutation in the affected sample. 
We reached three main results from this project: 
1) We developed a NGS analysis pipeline for trio family samples. 
We focused our effort to validate the accuracy of the variant 
calls and the homogeneity of the callable loci between the 
samples by comparing the read depth. 
2) We found a set of six candidate genes, which presented 
homozygous mutations in the affected sample coming from the 
heterozygous genotype of the parents. By looking at the 
biological process, the TRDN and the UNC45A were selected 
for segregation analysis. By segregation analysis with other 
unaffected individual in the family tree, we were not able to 
identify the causative variants. 
3) We also found de novo mutations, which could influence the 
disease effect. In detail, we found a potential damaging 
mutation in MFHAS1 gene that is related to malignant fibrous 
histiocytoma (MFH) onset and apparently is not related to a 
cardiac disease. This type of mutation can be catalogued in 
term of incidental finding result. 
Further investigation will need for this project to determine the disease-
causing variation by performing functional study on TRDN and UNC45A 
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genes. In addition, as for target sequencing pipeline, we will build a 
package for trio analysis as plug-in in a widely NGS data analysis pipeline. 
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6. APPENDIX 
6.1. Case 1: Target sequencing of 91 BrS patients 
The tables showed below reported supplementary information about the 
case study 1 such as the patient description, the target genes used for 
panel construction and the overall mutations found in the mutation analysis 
classified by the category described in the section 2.3.3 
6.1.1. BrS patients description 
Description N (%) 
Number of patients 91 
Follow-up (months, mean and st.dev.) 63.4 ± 21 
Age (years, mean and st.dev.) 50.5 ± 13.2 
Males 79 (87) 
Family history for SCD  27 (29) 
Spontaneous type I ECG 55 (60.4) 
Asymptomatic 35 (38.4) 
Syncope 25 (27.4) 
MAE (SCD, documented VT/VF, appropriate ICD 
shock) 
8 (8.7) 
Age at MAE (years, mean and st.dev.) 41 ± 12 
ICD implanted  55 (60) 
 
6.1.2. Genes panel for target sequencing 
Gene 
Name 
Protein description Ensembl ID Cathegory 
SCN1A sodium channel, voltage-gated, type I, alpha subunit ENSG00000144285 Sodium Channel alpha-subunit 
SCN2A sodium channel, voltage-gated, type II, alpha subunit ENSG00000136531 Sodium Channel alpha-subunit 
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Gene 
Name 
Protein description Ensembl ID Cathegory 
SCN3A sodium channel, voltage-gated, type III, alpha subunit ENSG00000153253 Sodium Channel alpha-subunit 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit ENSG00000007314 Sodium Channel alpha-subunit 
SCN5A  sodium channel, voltage-gated, type V, alpha subunit ENSG00000183873 Sodium Channel alpha-subunit 
SCN7A sodium channel, voltage-gated, type VII, alpha subunit ENSG00000136546 Sodium Channel alpha-subunit 
SCN8A 
sodium channel, voltage-gated, type VIII, alpha 
subunit 
ENSG00000196876 Sodium Channel alpha-subunit 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit ENSG00000169432 Sodium Channel alpha-subunit 
SCN10A sodium channel, voltage-gated, type X, alpha subunit ENSG00000185313 Sodium Channel alpha-subunit 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit ENSG00000168356 Sodium Channel alpha-subunit 
SCN1B sodium channel, voltage-gated, type I, beta subunit ENSG00000105711 Sodium Channel beta-subunit 
SCN2B  sodium channel, voltage-gated, type II, beta subunit ENSG00000149575 Sodium Channel beta-subunit 
SCN3B sodium channel, voltage-gated, type III, beta subunit ENSG00000166257 Sodium Channel beta-subunit 
SCN4B sodium channel, voltage-gated, type IV, beta subunit ENSG00000177098 Sodium Channel beta-subunit 
HCN1 
hyperpolarization activated cyclic nucleotide-gated 
potassium channel 1 
ENSG00000164588 
Potassium Channel alpha-
subunit 
HCN2 
hyperpolarization activated cyclic nucleotide-gated 
potassium channel 2 
ENSG00000099822 
Potassium Channel alpha-
subunit 
HCN3 
hyperpolarization activated cyclic nucleotide-gated 
potassium channel 3 
ENSG00000143630 
Potassium Channel alpha-
subunit 
HCN4  
hyperpolarization activated cyclic nucleotide-gated 
potassium channel 4 
ENSG00000138622 
Potassium Channel alpha-
subunit 
KCND1 
potassium voltage-gated channel, Shal-related 
subfamily, member 1 
ENSG00000102057 
Potassium Channel alpha-
subunit 
KCND2 
potassium voltage-gated channel, Shal-related 
subfamily, member 2 
ENSG00000184408 
Potassium Channel alpha-
subunit 
KCND3  
potassium voltage-gated channel, Shal-related 
subfamily, member 3 
ENSG00000171385 
Potassium Channel alpha-
subunit 
KCNE1 
potassium voltage-gated channel, Isk-related family, 
member 1 
ENSG00000180509 
Potassium Channel alpha-
subunit 
KCNE2 
potassium voltage-gated channel, Isk-related family, 
member 2 
ENSG00000159197 
Potassium Channel alpha-
subunit 
KCNE3 
potassium voltage-gated channel, Isk-related family, 
member 3 
ENSG00000175538 
Potassium Channel alpha-
subunit 
KCNE5 KCNE1-like ENSG00000176076 
Potassium Channel alpha-
subunit 
KCNQ1  
potassium voltage-gated channel, KQT-like subfamily, 
member 1 
ENSG00000053918 
Potassium Channel alpha-
subunit 
KCNQ2 
potassium voltage-gated channel, KQT-like subfamily, 
member 2 
ENSG00000075043 
Potassium Channel alpha-
subunit 
KCNH2 
potassium voltage-gated channel, subfamily H, 
member 2 
ENSG00000055118 
Potassium Channel alpha-
subunit 
KCNG1 
potassium voltage-gated channel, subfamily G, 
member 1 
ENSG00000026559 
Potassium Channel alpha-
subunit 
KCNG2 
potassium voltage-gated channel, subfamily G, 
member 2 
ENSG00000178342; 
Potassium Channel alpha-
subunit 
KCHIP2 Kv channel interacting protein 2 ENSG00000120049 
Potassium Channel alpha-
subunit 
KCNIP3 Kv channel interacting protein 3, calsenilin ENSG00000115041 
Potassium Channel alpha-
subunit 
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Gene 
Name 
Protein description Ensembl ID Cathegory 
KCNIP1 Kv channel interacting protein 1 ENSG00000182132 
Potassium Channel alpha-
subunit 
KCNK5  potassium channel, subfamily K, member 5 ENSG00000164626 
Potassium Channel alpha-
subunit 
KCNK3  potassium channel, subfamily K, member 3 ENSG00000171303 
Potassium Channel alpha-
subunit 
KCNK1  potassium channel, subfamily K, member 1 ENSG00000135750 
Potassium Channel alpha-
subunit 
KCNK6 potassium channel, subfamily K, member 6 ENSG00000099337 
Potassium Channel alpha-
subunit 
KCNK2 potassium channel, subfamily K, member 2 ENSG00000082482 
Potassium Channel alpha-
subunit 
KCNK4 potassium channel, subfamily K, member 4 ENSG00000182450 
Potassium Channel alpha-
subunit 
KCNK12 potassium channel, subfamily K, member 12 ENSG00000184261 
Potassium Channel alpha-
subunit 
KCNK17 potassium channel, subfamily K, member 17 ENSG00000124780 
Potassium Channel alpha-
subunit 
KCNA7 
potassium voltage-gated channel, shaker-related 
subfamily, member 7 
ENSG00000104848 
Potassium Channel alpha-
subunit 
KCNA2 
potassium voltage-gated channel, shaker-related 
subfamily, member 2 
ENSG00000177301 
Potassium Channel alpha-
subunit 
KCNA4  
potassium voltage-gated channel, shaker-related 
subfamily, member 4 
ENSG00000182255 
Potassium Channel alpha-
subunit 
KCNA5 
potassium voltage-gated channel, shaker-related 
subfamily, member 5 
ENSG00000130037 
Potassium Channel alpha-
subunit 
KCNA6 
potassium voltage-gated channel, shaker-related 
subfamily, member 6 
ENSG00000151079 
Potassium Channel alpha-
subunit 
KCNB1 
potassium voltage-gated channel, Shab-related 
subfamily, member 1 
ENSG00000158445 
Potassium Channel alpha-
subunit 
KCNB2 
potassium voltage-gated channel, Shab-related 
subfamily, member 2 
ENSG00000182674 
Potassium Channel alpha-
subunit 
KCNC3  
potassium voltage-gated channel, Shaw-related 
subfamily, member 3 
ENSG00000131398 
Potassium Channel alpha-
subunit 
KCNF1 
potassium voltage-gated channel, subfamily F, 
member 1 
ENSG00000162975 
Potassium Channel alpha-
subunit 
KCNJ2 
potassium inwardly-rectifying channel, subfamily J, 
member 2 
ENSG00000123700 
Potassium Channel alpha-
subunit 
KCNJ3 
potassium inwardly-rectifying channel, subfamily J, 
member 3 
ENSG00000162989 
Potassium Channel alpha-
subunit 
KCNJ4 
potassium inwardly-rectifying channel, subfamily J, 
member 4 
ENSG00000168135 
Potassium Channel alpha-
subunit 
KCNJ5  
potassium inwardly-rectifying channel, subfamily J, 
member 5 
ENSG00000120457 
Potassium Channel alpha-
subunit 
KCNJ8 
potassium inwardly-rectifying channel, subfamily J, 
member 8 
ENSG00000121361 
Potassium Channel alpha-
subunit 
KCNJ11  
potassium inwardly-rectifying channel, subfamily J, 
member 11 
ENSG00000187486 
Potassium Channel alpha-
subunit 
KCNJ6 
potassium inwardly-rectifying channel, subfamily J, 
member 6 
ENSG00000157542 
Potassium Channel alpha-
subunit 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, ENSG00000157551 Potassium Channel alpha-
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Gene 
Name 
Protein description Ensembl ID Cathegory 
member 15 subunit 
KCNJ12 
potassium inwardly-rectifying channel, subfamily J, 
member 12 
ENSG00000184185 
Potassium Channel alpha-
subunit 
KCNN3 
potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 3 
ENSG00000143603 
Potassium Channel alpha-
subunit 
KCNS3 
potassium voltage-gated channel, delayed-rectifier, 
subfamily S, member 3 
ENSG00000170745 
Potassium Channel alpha-
subunit 
KCNAB1 
potassium voltage-gated channel, shaker-related 
subfamily, beta member 1 
ENSG00000169282 Potassium Channel beta-subunit 
KCNAB2 
potassium voltage-gated channel, shaker-related 
subfamily, beta member 2 
ENSG00000069424 Potassium Channel beta-subunit 
KCNAB3 
potassium voltage-gated channel, shaker-related 
subfamily, beta member 3 
ENSG00000170049 Potassium Channel beta-subunit 
CLCN2 chloride channel, voltage-sensitive 2 ENSG00000114859 Chloride Channel 
CLCN3 chloride channel, voltage-sensitive 3 ENSG00000109572 Chloride Channel 
CLCN6 chloride channel, voltage-sensitive 6 ENSG00000011021 Chloride Channel 
CLCN7 chloride channel, voltage-sensitive 7 ENSG00000103249 Chloride Channel 
CACNA1
A 
calcium channel, voltage-dependent, P/Q type, alpha 
1A subunit 
ENSG00000141837 Calcium Channel 
CACNA1
C  
calcium channel, voltage-dependent, L type, alpha 1C 
subunit 
ENSG00000151067 Calcium Channel 
CACNA1
D 
calcium channel, voltage-dependent, L type, alpha 1D 
subunit 
ENSG00000157388 Calcium Channel 
CACNA1
E 
calcium channel, voltage-dependent, R type, alpha 1E 
subunit 
ENSG00000198216 Calcium Channel 
CACNA1
G  
calcium channel, voltage-dependent, T type, alpha 1G 
subunit 
ENSG00000006283 Calcium Channel 
CACNA1
H 
calcium channel, voltage-dependent, T type, alpha 1H 
subunit 
ENSG00000196557 Calcium Channel 
CACNA2
D1 
calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
ENSG00000153956 Calcium Channel 
CACNA2
D2 
calcium channel, voltage-dependent, alpha 2/delta 
subunit 2 
ENSG00000007402 Calcium Channel 
CACNB2  calcium channel, voltage-dependent, beta 2 subunit ENSG00000165995 Calcium Channel 
ADRB1 adrenoceptor beta 1 ENSG00000043591 
Ligand-dependent Gated 
Channel 
ADRB2 adrenoceptor beta 2 ENSG00000169252 
Ligand-dependent Gated 
Channel 
CHRM2 cholinergic receptor, muscarinic 2 ENSG00000181072 
Ligand-dependent Gated 
Channel 
CHRNA3  cholinergic receptor, nicotinic, alpha 3 ENSG00000080644 
Ligand-dependent Gated 
Channel 
CHRNB2 cholinergic receptor, nicotinic, beta 2 ENSG00000160716 
Ligand-dependent Gated 
Channel 
CNP natriuretic peptide C ENSG00000163273 
Ligand-dependent Gated 
Channel 
NGF nerve growth factor ENSG00000134259 
Ligand-dependent Gated 
Channel 
NRG1  neuregulin 1 ENSG00000157168 
Ligand-dependent Gated 
Channel 
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Gene 
Name 
Protein description Ensembl ID Cathegory 
SLC6A4 solute carrier family 6 ENSG00000108576 
Ligand-dependent Gated 
Channel 
ANK1 ankyrin 1 ENSG00000029534 Ankyrins 
ANK2 ankyrin 2 ENSG00000145362 Ankyrins 
ANK3 ankyrin 3 ENSG00000151150 Ankyrins 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide ENSG00000163399 Ion exchangers 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide ENSG00000105409 Ion exchangers 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide ENSG00000143153 Ion exchangers 
ATP2A2 
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
ENSG00000174437 Ion exchangers 
ATP2A3 ATPase, Ca++ transporting, ubiquitous ENSG00000074370 Ion exchangers 
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 ENSG00000070961 Ion exchangers 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 ENSG00000058668 Ion exchangers 
SLC8A1  
(NCX1) 
solute carrier family 8 (sodium/calcium exchanger), 
member 1 
ENSG00000183023 Ion exchangers 
CALM1 calmodulin 1 ENSG00000198668 
scaffold and calcium binding 
proteins  
CALM3 calmodulin 3 ENSG00000160014 
scaffold and calcium binding 
proteins  
CALR calreticulin ENSG00000179218 
scaffold and calcium binding 
proteins  
CASQ1 calsequestrin 1 ENSG00000143318 
scaffold and calcium binding 
proteins  
CASQ2  calsequestrin 2 ENSG00000118729 
scaffold and calcium binding 
proteins  
CAV1 caveolin 2 ENSG00000105974 
scaffold and calcium binding 
proteins  
CAV2 caveolin 2 ENSG00000105971 
scaffold and calcium binding 
proteins  
CAV3 caveolin 3 ENSG00000182533 
scaffold and calcium binding 
proteins  
DSC2 desmocollin 2 ENSG00000134755 
scaffold and calcium binding 
proteins  
DSG2  desmoglein 2 ENSG00000046604 
scaffold and calcium binding 
proteins  
DSP desmoplakin ENSG00000096696 
scaffold and calcium binding 
proteins  
JUP junction plakoglobin ENSG00000173801 
scaffold and calcium binding 
proteins  
SNTA1 syntrophin, alpha 1 ENSG00000101400 
scaffold and calcium binding 
proteins  
SNTB1 syntrophin, beta 1 ENSG00000172164 
scaffold and calcium binding 
proteins  
SNTB2 syntrophin, beta 2 ENSG00000168807 
scaffold and calcium binding 
proteins  
SNTG2 syntrophin, gamma 2 ENSG00000172554 
scaffold and calcium binding 
proteins  
GJA1 gap junction protein, alpha 1 ENSG00000152661 gap junctions  
GJA5 gap junction protein, alpha 5 ENSG00000143140 gap junctions  
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Gene 
Name 
Protein description Ensembl ID Cathegory 
GJA7 
(GJC1) 
gap junction protein, gamma 1 ENSG00000182963 gap junctions  
ACTC1 actin, alpha, cardiac muscle 1 ENSG00000159251 structural proteins  
ACTN2 actinin, alpha 2 ENSG00000077522 structural proteins  
LMNA lamin A/C ENSG00000160789 structural proteins  
MYH6 myosin, heavy chain 6 ENSG00000197616 structural proteins  
MYH7 myosin, heavy chain 7 ENSG00000092054 structural proteins  
 TELT  titin-cap ENSG00000173991 structural proteins  
DES desmin ENSG00000175084 structural proteins  
ACE  angiotensin I converting enzyme ENSG00000159640 Other 
AGTR1 angiotensin II receptor, type 1 ENSG00000144891 Other 
AGTR2 angiotensin II receptor, type 2 ENSG00000180772 Other 
AKAP9  A kinase (PRKA) anchor protein (yotiao) 9 ENSG00000127914 Other 
AR androgen receptor ENSG00000169083 Other 
CNOT1 CCR4-NOT transcription complex, subunit 1 ENSG00000125107 Other 
CXADR coxsackie virus and adenovirus receptor ENSG00000154639 Other 
FGF12 fibroblast growth factor 12 ENSG00000114279 Other 
GPD1 glycerol-3-phosphate dehydrogenase 1 ENSG00000167588 Other 
GPD1L glycerol-3-phosphate dehydrogenase 1-like ENSG00000152642 Other 
ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 ENSG00000150995 Other 
KNG1 kininogen 1 ENSG00000113889 Other 
LITAF lipopolysaccharide-induced TNF factor ENSG00000189067 Other 
MDR1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
ENSG00000085563 Other 
NDRG4 NDRG family member 4 ENSG00000103034 Other 
NEDD 4 
neural precursor cell expressed, developmentally 
down-regulated 4, E3 ubiquitin protein ligase 
ENSG00000069869 Other 
NEDD4L 
neural precursor cell expressed, developmentally 
down-regulated 4-like, E3 ubiquitin protein ligase 
ENSG00000049759 Other 
NOS1AP nitric oxide synthase 1 (neuronal) adaptor protein ENSG00000198929 Other 
NPPA natriuretic peptide A ENSG00000175206 Other 
NPPB natriuretic peptide B ENSG00000120937 Other 
NRG3  neuregulin 3 ENSG00000185737 Other 
PKP2 plakophilin 2 ENSG00000057294 Other 
PLN phospholamban ENSG00000198523 Other 
PPP3CA  
protein phosphatase 3, catalytic subunit, alpha 
isozyme 
ENSG00000138814 Other 
PSEN1 presenilin 1 ENSG00000080815 Other 
PSEN2 presenilin 2 ENSG00000143801 Other 
PTPH1 protein tyrosine phosphatase, non-receptor type 3 ENSG00000070159 Other 
RANGR
F 
RAN guanine nucleotide release factor ENSG00000160789 Other 
RYR2 ryanodine receptor 2 ENSG00000198626 Other 
PIAS3 protein inhibitor of activated STAT, 3 ENSG00000131788 
Potassium Channel alpha-
subunit 
TBX5 T-box 5 ENSG00000089225 Other 
TGFB3 transforming growth factor, beta 3 ENSG00000119699 Other 
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Name 
Protein description Ensembl ID Cathegory 
TMEM 
43  
Transmembrane protein 43 ENSG00000170876 Other 
YWHAH  
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide 
ENSG00000128245 Other 
 
6.1.3. List of NS-SNVs 
Sample Chr Pos Ref Alt AA Chage Gene Name 
Brugada_73683 10 61819149 C T C1682Y ANK3 
Brugada_061826 10 61822964 A G V146A ANK3 
Brugada_101728 10 61831718 T A N2974I ANK3 
Brugada_84973 10 61835330 G C T1770R ANK3 
Brugada_8467 1 111147277 C T R43Q KCNA2 
Brugada_061826 1 145584024 C T P384S PIAS3 
Brugada_73051 1 145584179 A G K409E PIAS3 
Brugada_53353 1 145584276 C T P441L PIAS3 
Brugada_061826 1 155257090 C T A535V HCN3 
Brugada_74659 1 156085059 A G K117R LMNA 
Brugada_8579 1 156085059 A G K117R LMNA 
Brugada_09172 1 160163637 T G D149E CASQ1 
Brugada_10578 1 162257218 A G K88E NOS1AP 
Brugada_93200 1 181689358 C T R197W CACNA1E 
Brugada_71746 1 181690939 C T R275C CACNA1E 
Brugada_84973 1 203696604 G A D1036N ATP2B4 
Brugada_81290 1 237617717 C A A424E RYR2 
Brugada_101196 1 237711861 C T R1011W RYR2 
Brugada_93200 1 237811912 C T T2488M RYR2 
Brugada_93793 12 50501160 T C M173T GPD1 
Brugada_74487 12 50501193 G A G184E GPD1 
Brugada_091856 12 50501362 G A V186M GPD1 
Brugada_92497 12 52100339 G A R290H SCN8A 
Brugada_73980 14 23853673 C T R1848H MYH6 
Brugada_72060 14 23863351 G A R871C MYH6 
Brugada_74200 14 23886163 C T G1520R MYH7 
Brugada_103377 14 76425594 A G V392A TGFB3 
Brugada_7376 15 56125285 A C D1163E NEDD4 
Brugada_73051 15 78893644 C T S254N CHRNA3 
Brugada_6582 15 78921890 C T V253I CHRNB4 
Brugada_72060 16 1251967 G A R506Q CACNA1H 
Brugada_73051 16 1254406 T C M800T CACNA1H 
Brugada_63555 16 1259233 C T R1189C CACNA1H 
Brugada_5258 16 1260047 C T R1253C CACNA1H 
Brugada_84023 16 1260902 C T S1385L CACNA1H 
Brugada_062107 16 1510492 A G F116S CLCN7 
Brugada_93793 16 58589261 T C M358V CNOT1 
Brugada_63620 17 28543101 C G G324A SLC6A4 
Brugada_08404 17 3844281 T C N695S ATP2A3 
Brugada_74159 17 48703921 C G P2109A CACNA1G 
Brugada_072337 17 62026786 C T E986K SCN4A 
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Brugada_74200 17 62029217 G A A807V SCN4A 
Brugada_95342 18 28672091 T C I109M DSC2 
Brugada_93061 18 29122693 G A A738T DSG2 
Brugada_09172 18 29122733 C T T751I DSG2 
Brugada_103905 19 13323494 G A P2001S CACNA1A 
Brugada_83255 19 49573517 C T V392I KCNA7 
Brugada_092178 20 62038356 C T A723T KCNQ2 
Brugada_73051 2 1094040 G A G90E SNTG2 
Brugada_72939 2 1251167 G C K192N SNTG2 
Brugada_71603 21 35742967 A G I64V KCNE2 
Brugada_103969 21 39668946 G A Splicing KCNJ15 
Brugada_81290 2 166172087 G A S497N SCN2A 
Brugada_63620 2 166246047 A G I1911V SCN2A 
Brugada_62293 2 166848701 A G V1667A SCN1A 
Brugada_61687 2 166892998 C T A969T SCN1A 
Brugada_95342 2 167060467 A G V1580A SCN9A 
Brugada_73370 2 167298099 T C E655G SCN7A 
Brugada_62396 2 18113554 G T D427Y KCNS3 
Brugada_95342 2 40404894 T G K637T SLC8A1 
Brugada_72939 3 155861029 C T S21F KCNAB1 
Brugada_101728 3 38648255 C T D349N SCN5A 
Brugada_72939 3 38768095 A G Splicing SCN10A 
Brugada_6583 3 38805052 G A S212L SCN10A 
Brugada_71603 3 38888249 T C Q1733R SCN11A 
Brugada_08404 3 38968422 C G E163D SCN11A 
Brugada_72900 3 4741557 G A E1466K ITPR1 
Brugada_53353 3 4810254 G A A1866T ITPR1 
Brugada_71563 3 4842201 C T R2279W ITPR1 
Brugada_8579 3 50402321 T C T1030A CACNA2D2 
Brugada_92497 3 50410496 C T D669N CACNA2D2 
Brugada_061826 3 50413411 C T D517N CACNA2D2 
Brugada_91596 4 114239689 A T K147M ANK2 
Brugada_103969 4 114264197 G A V1296I ANK2 
Brugada_73980 4 114276621 A C K2250Q ANK2 
Brugada_73370 4 114276847 G A S2325N ANK2 
Brugada_93061 4 114284568 G A D1517N ANK2 
Brugada_103905 4 170639007 G A V811I CLCN3 
Brugada_62293 5 170162766 G A D175N KCNIP1 
Brugada_101912 7 120385982 G T R539L KCND2 
Brugada_62293 7 91726634 G A R1300Q AKAP9 
Brugada_061826 8 121554142 T C I478V SNTB1 
Brugada_72900 8 32620767 A T K434* NRG1 
Brugada_8265 8 32620793 G T Q442H NRG1 
Brugada_09172 X 66766051 G C E165Q AR 
 
6.1.4. List of novel coding HQ-INDELs 
Sample Chr Pos Ref Alt AA change Variant effect 
Gene 
name 
Brugada_072337 1 154541997 TA T - Frame Shift CHRNB2 
Brugada_092178 4 114214678 TCAC T VT29V Codon deletion ANK2 
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Sample Chr Pos Ref Alt AA change Variant effect 
Gene 
name 
Brugada_103220 1 116243874 ATCG A DD324D Codon deletion CASQ2 
Brugada_103377 19 50819304 C CG - Frame Shift KCNC3 
Brugada_103969 14 23858896 
CTCCAGCG
TCCGAGA C - Frame Shift MYH6 
Brugada_6582 6 39278694 AAAG A FF108F Codon deletion KCNK17 
Brugada_74659 3 184071131 C CCGG R601PG Codon insertion CLCN2 
Brugada_84023 3 148458931 A AT - Frame Shift AGTR1 
Brugada_84023 17 28548775 TG T - Frame Shift SLC6A4 
Brugada_85255 3 184071131 C CCGG R601PG Codon insertion CLCN2 
Brugada_92497 6 39278694 AAAG A FF108F Codon deletion KCNK17 
Brugada_92497 19 615946 
CCCGCCG
CCG C PPP715- Codon deletion HCN2 
Brugada_93103 3 38968409 C CAGTGAAGA - Frame Shift SCN11A 
 
6.1.5. List of clinical rs 
Sample Chr Pos dbSNP137_ID AA change Variant Effect Gene Name 
Brugada_6582 1 236849999 rs121434525 Q9R Non-Synonymous ACTN2 
Brugada_101411 5 148206885 rs1800888 T164I Non-Synonymous ADRB2 
Brugada_53353 5 148206885 rs1800888 T164I Non-Synonymous ADRB2 
Brugada_73683 5 148206885 rs1800888 T164I Non-Synonymous ADRB2 
Brugada_10552 X 115303595 rs121917810 G21V Non-Synonymous AGTR2 
Brugada_72060 X 115303595 rs121917810 G21V Non-Synonymous AGTR2 
Brugada_101912 4 114294537 rs45454496 E1022K Non-Synonymous ANK2 
Brugada_61687 4 114294537 rs45454496 E1022K Non-Synonymous ANK2 
Brugada_6582 4 114286207 rs66785829 V1540D Non-Synonymous ANK2 
Brugada_73683 4 114269433 rs72544141 E110G Non-Synonymous ANK2 
Brugada_74159 4 114294462 rs121912706 R1812W Non-Synonymous ANK2 
Brugada_73051 3 8775526 rs116840771 - Transcript C3orf32 
Brugada_74487 3 8787514 rs147250678 V139 Synonymous CAV3 
Brugada_101728 3 184075476 rs71318369 R191Q Non-Synonymous CLCN2 
Brugada_08240 18 29126057 rs34065672 T903I Non-Synonymous DSG2 
Brugada_08240 18 29125996 rs34417028 S883P Non-Synonymous DSG2 
Brugada_91857 18 29099850 rs121913013 V56M Non-Synonymous DSG2 
Brugada_08404 6 7542236 rs121912998 V30M Non-Synonymous DSP 
Brugada_7269 6 7542253 rs77445784 G35 Synonymous DSP 
Brugada_85255 6 7542236 rs121912998 V30M Non-Synonymous DSP 
Brugada_08240 17 39923625 rs193922705 - Downstream JUP 
Brugada_63684 17 39923625 rs193922705 - Downstream JUP 
Brugada_62293 21 35821904 rs144917638 T10M Non-Synonymous KCNE1 
Brugada_74159 21 35743006 rs141423405 R77W Non-Synonymous KCNE2 
Brugada_93238 21 35742947 rs74315448 I57T Non-Synonymous KCNE2 
Brugada_08404 7 150642586 rs199473032 A1020V Non-Synonymous KCNH2 
Brugada_103220 7 150648918 rs143011005 I181 Synonymous KCNH2 
Brugada_91596 7 150648918 rs143011005 I181 Synonymous KCNH2 
Brugada_7650 5 170149737 rs147147696 S116 Synonymous KCNIP1 
Brugada_83255 11 2608850 rs12720457 K266N Non-Synonymous KCNQ1 
Brugada_92497 20 62039895 rs118192239 - Downstream KCNQ2 
Brugada_91490 1 156104292 rs12117552 L105 Synonymous LMNA 
Brugada_9544 1 156084760 rs11549668 S17 Synonymous LMNA 
Brugada_74659 14 23887607 rs141764279 N1327 Synonymous MYH7 
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Sample Chr Pos dbSNP137_ID AA change Variant Effect Gene Name 
Brugada_101411 1 237604747 rs193922621 D362 Synonymous RYR2 
Brugada_101728 1 237948286 rs141528541 - Intronic RYR2 
Brugada_101728 1 237872887 rs74323916 - Intronic RYR2 
Brugada_103905 1 237948286 rs141528541 - Intronic RYR2 
Brugada_63216 1 237875068 rs138073811 N3402 Synonymous RYR2 
Brugada_63447 1 237811766 rs72549416 D2439 Synonymous RYR2 
Brugada_7376 1 237875068 rs138073811 N3402 Synonymous RYR2 
Brugada_81290 1 237811889 rs143906555 L2480 Synonymous RYR2 
Brugada_93103 1 237664004 rs147479514 - Intronic RYR2 
Brugada_95342 1 237948286 rs141528541 - Intronic RYR2 
Brugada_101196 2 166900411 rs121918769 R604H Non-Synonymous SCN1A 
Brugada_72939 2 166900411 rs121918769 R604H Non-Synonymous SCN1A 
Brugada_091856 17 62028920 rs41280102 S906T Non-Synonymous SCN4A 
Brugada_53609 17 62028920 rs41280102 S906T Non-Synonymous SCN4A 
Brugada_7975 17 62028920 rs41280102 S906T Non-Synonymous SCN4A 
Brugada_9346 17 62028920 rs41280102 S906T Non-Synonymous SCN4A 
Brugada_95342 17 62028920 rs41280102 S906T Non-Synonymous SCN4A 
Brugada_711 3 38601665 rs41311123 G1352 Synonymous SCN5A 
Brugada_73980 3 38601665 rs41311123 G1352 Synonymous SCN5A 
Brugada_74487 3 38628879 rs41312419 - Intronic SCN5A 
Brugada_8467 3 38597180 rs45548237 S1449 Synonymous SCN5A 
Brugada_93061 3 38597180 rs45548237 S1449 Synonymous SCN5A 
Brugada_95342 3 38620970 rs199473189 V1081A Non-Synonymous SCN5A 
Brugada_092178 2 167138296 rs121908919 K520R Non-Synonymous SCN9A 
Brugada_81713 2 167159672 rs121908916 R142 Synonymous SCN9A 
Brugada_09172 17 28538374 rs28914832 I425V Non-Synonymous SLC6A4 
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